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Both academic institutions and pharmaceutical companies have invested a lot of 
effort to develop anticancer drugs which would allow regulation of pathways 
underlying the uncontrollable cell division. In parallel, for the successful treat-
ment of cancer, it is of utmost importance to work out ‘easy-to-use’ diagnostic 
tools. Cell division (including mitotic events) is orchestrated by crosstalk of 
different protein kinases – the enzymes that carry out phosphorylation reaction, 
through which the processes necessary for the excistence of cell are regulated. 
Protein kinases are also under study as biomarkers, as the altered activity and/or 
concentration of kinases may indicate the presence of certain disease. The 
practical importance of protein kinase research is also demonstrated by the fact 
that 39 inhibitors targeting protein kinases are approved as drugs by US Food 
and Drug Administration (FDA).1,2  
The current thesis describes development of compounds targeting mitotic 
kinase Haspin. Haspin is an important regulator of mitotic events and had been 
acknowledged as a ‘promising target for the design of inhibitors as potent anti-
cancer drugs’.3 Novel Haspin-targeting compounds were constructed using 
principles of design of bisubstrate-analogue inhibitors (adenosine analogue-
oligoarginine conjugates or ARCs), where the ATP-site targeting fragment and 
substrate analogue of protein kinase were interconnected by a flexible linker. 
The design was guided by the structural information revealed from the results of 
X-ray analysis of co-crystals of complexes of Haspin and inhibitors. The 
stability and the kinetics of formation and dissociation of complexes of con-
jugates with Haspin as well as the selectivity of these fundamental properties 
for binding with some other protein kinases were established in biochemical 
studies. As a result of precise targeting of ‘binding hotspots’ of active site of 
Haspin the conjugates with high affinity and selectivity were obtained. This 











1. Protein Kinases 
1.1. General Properties 
Protein kinases (PKs) are the enzymes that catalyse the phosphorylation of 
substrate proteins, resulting in transfer of the γ-phophoryl group (PO32-) from 
the donor molecule (generally ATP) to Ser, Thr or Tyr residue of the substrate 
protein (Scheme 1). Thereby, dual negative charge is introduced into the struc-
ture of substrate and drastic change in hydrogen bond properties of the sub-site 
from a donor to acceptor induced, causing the change of conformation of the 
protein. Hence, the phosphorylation is functioning as a molecular switch by 
turning the cellular signalling pathways ‘ON’ or ‘OFF’.4,5  
 
MgATP-1 + protein-OH  protein-OPO32- + MgADP + H+ 
 
Scheme 1. General scheme of phosphorylation of substrate proteins catalysed by PKs. 
 
 
Phosphorylation level of proteins is highly controlled and balanced by dephos-
phorylation, which is carried out by phosphoprotein phosphatases.6 Thus, the 
reversible character of phosphorylation-dephosphorylation processes is of 
utmost importance in cellular functioning, i.e., regulation of metabolic path-
ways, membrane transport, cell division and movement, cell growth and diffe-
rentiation, and controlled cell death (apoptosis). Consequently, the dysregu-
lation of PKs is associated with many diseases, including cancer, inflammatory 
diseases, autoimmune diseases, Alzheimer disease, hypertension.4,6 Thus, over 
the past decades PKs have become major drug targets as well as targets of 
intense biotechnological research both in academia and in pharmaceutical 
companies.1,4,7 
Human PK gene family includes 538 members (initial human genome se-
quencing report announced 518 PKs8) coded by approximately 2.7% of genes in 
human genome (ca 19,000–20,000 human protein-coding genes in total).5,9 
Based on the nature of phosphorylatable hydroxyl group in the preferred sub-
strates, i.e., alcoholic (Ser or Thr) or phenolic (Tyr), PKs are classified into 
serine/threonine PKs and tyrosine PKs, respectively.4,5 Furthermore, some PKs 
are able to phosphorylate both types of hydroxyl group and thus are termed as 
dual specificity PKs (e.g., dual specificity tyrosine-phosphorylation regulated 
kinases, DYRKs).5 In addition to the single site phosphorylation, the substrates 
may also be phosphorylated at multiple sites, whereas it is possible that the sub-
sequent phosphorylation can be facilitated by previous one. This phenomenon is 
named ‘priming phosphorylation’, whereas the second phosphorylation may be 
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ca 100–1000 times more efficient in the presence of the priming phosphoryl 
than without priming.10,11 
Generally, most PKs contain K/E/D/D signature sequence in catalytic loop 
and require divalent cations, such as Mg2+ (or Mn2+), for catalysis (see Scheme 
1). Still, 50 PKs out of 538 are so-called pseudokinases which lack the cataly-
tically important residues (e.g., absence of αGlu or β3-Lys, changes in the DFG 
or HRD signatures; see below in sections 1.1.2. General Structural Features of 
PKs on the Example of PKA C and 2.2.2. Comparison of Crystal Structures of  
Catalytical Domains of Haspin and PKA) and hence do not possess catalytic 
activity. Still, it has been shown that pseudokinases may act as regulators of 
catalytically active PKs, function as scaffolding entities (i.e., form complexes 
with other proteins and recruit those to certain locations in cells), and protect 
their ‘partners’ against the phosphorylation by other PKs.4,5,12,13  
Activation of PKs is achieved by different mechanisms. For instance, many 
PKs require the phosphorylation (auto-phosphorylation or phosphorylation 
mediated by other kinases) of one or several Ser, Thr or Tyr residues in their 
activation loop (also termed as T-loop), which runs between the conserved DFG 
and APE motifs (see below). Usually, this phosphorylation leads to the con-
formational changes allowing the right positioning of residues required for the 
substrate binding and catalysis. Moreover, structural rearrangement causes the 
loss of steric hindrance and hence allows the access of substrate into the active 
site. The activity of PKs may also be regulated via recruitment of second 
messengers (molecular cofactors), such as binding of cAMP molecules to R-
subunits of PKA (see below in section 1.1.1. PKA C as a Prototype of PKs), or 
by additional subunits and regulatory proteins whose expression level is 
adjustable (e.g., the concentration of cyclins that activate cyclin-dependent PKs, 
Cdks varies throughout the cell cycle).6,14 
 
 
1.1.1. PKA C as a Prototype of PKs 
cAMP-dependent protein kinase or protein kinase A (PKA) is one of the first 
discovered (Walsh et al. in 196815) and well studied PKs due to its clear 
activation mechanism and structural similarities with other eukaryotic PKs 
(ePKs).14,16,17 As PKA is abundant in organisms, it participates in various sig-
nalling cascades: it has several important functions including destabilization of 
cytoskeleton via regulation of dynamics of F-actin, relaxation of heart muscles, 
lipolysis in adipose tissue, antigen induced activation of B- and T-cells, gene 
expression (by phosphorylating cellular transcription factor nuclear cAMP-
response element-binding protein, CREB).18–20 
The first crystal structure of the active site of a PK was that of the catalytic 
subunit α of PKA (PKA C) and it was published in 199121, paving the road for 
the X-ray study of 3D-structure of PKs. PKA C is often also used as a prototype 
of PKs because of its structural similarities with other ePKs: globular bilobal 
structure, type and localization of catalytically important amino acid residues 
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(AAs), localization of binding sites for phosphoryl group donor and acceptor, 
etc. Moreover, the concentration of PKA in tissues is relatively high (e.g., 
concentration of 3.1 μM of PKA C in human platelets22), its recombinant form 
can be easily over-expressed and high yields can be achieved during the puri-
fication of the kinase.14,16 Besides, PKA possesses good properties for crystal-
lization, making possible its use as an ‘ersatz’-PK for modelling of kinases that 
are problematic from the aspect of purification or crystallization (e.g., Aurora 
kinases). For this, to obtain the maximum similarity with desired PK, point 
mutations are introduced into the sequence of DNA of the target PK, resulted in 
the change in the amino acid composition of PKA.23 
In its inactive state, PKA is a heterotetrameric holoenzyme containing two 
catalytic subunits (C) and a dimer of regulatory subunits (R). In humans, there 
are four types of R-subunits (RIα, RIβ, RIIα, RIIβ) and three types of C-
subunits (Cα/β/γ) that differ from each other not only by primary structure, but 
also by localization and expression level.4,24 Furthermore, other differences 
include that RI subunits require the presence of MgATP for the high-affinity 
binding to C-subunits.16,18 The activation of PKA is mediated by binding of 
second messenger 3´,5´-cyclic adenosine monophosphate (cAMP) to the regu-
latory subunits of PKA. For the activation, two cAMP molecules bind to each 
regulatory subunit, triggering the change of the structure of R-subunits and thus 
decreasing the affinity of R-subunits towards C-subunits. Consequently, the 
complex dissociates into a dimer of R-subunits and two active C-subunits, 
allowing the free active C-subunits to phosphorylate the Ser and/or Thr 
residue(s) of downstream substrates of PKA (Scheme 2).4,25 
 
R2C2 + 4 cAMP ⇔ R2(cAMP)4 + 2 C → phosphorylation of substrates of PKA 
 
Scheme 2. Activation mechanism of PKA: binding of 4 cAMP molecules to the dimer 
of regulatory subunits leads to dissociation of PKA holenzyme. 
 
 
Similary to other signal-transduction cascades, cAMP-PKA pathway is under 
strict spatiotemporal control to maintain the signalling specificity on the cellular 
level. In cell, signalling nodes are present which combine the enzymes that 
produce cAMP (adenylate cyclase), decompose cAMP (phosphodiesterases), 
utilize cAMP (PKA), and enable restoration of the initial phosphorylation levels 
(phosphoprotein phosphatases). These nodes are held together by so-called A-
kinase-anchoring proteins or AKAPs, which are responsible for the appropiate 
positioning of the aforementioned enzymes to subcellular locations. Thereby, 
the nodes are essentally able to function independently from each other and thus 





1.1.2. General Structural Features of PKs on the Example of PKA C 
The structure of catalytic domain of PKs is relatively conserved among the 
super-family of proteins. PKs have a globular structure and are composed of 
two major domains – smaller N- and larger C-terminal lobe – which are formed 
of mainly β-sheets (5 β-strands + 1 α-helix) and α-helixes, respectively (Figure 
1). The major domains are, in turn, further divided into 11 subdomains. The 
lobes are linked by the single polypeptide, known as the hinge or linker region, 
allowing rotation of the domains during binding of ATP to the cavity formed 
between the lobes (ATP-binding pocket), which is conserved in the family of 
PKs.4,5,14,28–30 The front side of ATP-pocket contains the residues important for 
the catalysis as well as for binding of ATP; at the same time, the back of hydro-
phobic pocket is responsible for the regulation of kinase activity (hydrophobic 
spines, see below).5 The substrate binds to the site locating on the surface of 
larger C-lobe, whereas the phosphorylatable Ser or Thr residue is directed to the 
cleft between the domains. Importantly, the substrate-binding site is less con-
served among PKs, hence making more attractive construction of compounds 
targeting the substrate site.4,5,14,28–30   
 
Figure 1. Structural features of PKs as exemplified by the co-crystal structure of PKA 
C with ATP and PKI(5-24) (PDB 1ATP). The PK is shown as a cartoon; ATP and 
PKI(5-24) are presented as sticks. G-rich loop is coloured black, activation segment 












As noted above, the highly conserved cleft between N- and C-terminal lobes is 
functioning as the docking site for ATP, whereas the main contribution to the 
nucleotide binding comes from the N-lobe. ATP is anchored to the pocket 
through the hydrogen bonds formed between the adenine moiety and residues in 
the hinge region, and between the ribose ring and residues in C-terminal domain. 
In the N-lobe, an extremely flexible and highly conserved glycine-rich loop (G-
rich loop) runs over the ATP-binding cleft (Figure 1, Figure 2). It contains the 
signature sequence GxGxΦG (where x corresponds to any AA and Φ 
corresponds to hydrophobic residue) and contributes to the nucleotide binding. 
The G-rich loop of PKA consists of the AA sequence 50GTGSFG55, where 
Phe54 and Gly55 anchor the β-phosphate of ATP (note: here and in the 
following text the numbering of AAs of PKA corresponds to PKA C). On the 
other hand, the amino and hydroxyl groups of Ser53 develop hydrogen bonds 
with γ-phosphate and Gly52 and Gly55 give the interactions with each 




Figure 2. Co-crystal structure of ATP with PKA C (PDB 1ATP). The PK is shown as a 
cartoon; ATP is presented in ball-and-sticks mode. G-rich loop is coloured black, acti-
vation segment green, hinge region blue, and αC-helix magenta. Residues of PK 
forming interactions with the co-crystallized ATP are shown as lines and are labelled; 






The β3-strand in N-lobe usually contains the sequence Ala-X-Lys, where the 
amino group of Lys (Lys72 in PKA) forms a salt bridge with the carboxyl group 
of conserved glutamate (Glu91 in PKA) in the centre of αC-helix (Figure 2). 
The salt bridge is a hallmark of active kinase as this interaction is crucial for the 
open conformation of the kinase (see below) and hence the catalytic activity of 
PK (generally, in the inactive state of enzyme, the salt bridge between β3-Lys 
and αC-Glu is absent). Furthermore, Lys72 of β3-strand in PKA gives the extra 
stabilizing interactions with α- and β-phosphates of ATP (Figure 2).4,14  
The adenine base of ATP gives hydrophilic as well as hydrophobic inter-
actions with residues in the ATP-binding site. In particular, the N6 of adenine 
base gives interaction with carbonyl oxygen of Glu121 (first AA in the hinge 
region) in PKA (Figure 2). Moreover, the N1 and N7 form H-bonds with amino 
group of Val123 (hinge region) and hydroxyl group of Thr183 (activation 
segment, see below). In addition to hydrophilic interactions, the adenine base 
gives interactions with hydrophobic residues from the N-lobe (Leu49, Val57, 
Ala70, Met120, Tyr122) as well as C-lobe (Leu173).4  
The C-lobe includes a mobile activation segment participating in the tran-
sition between the open (active enzyme) and closed conformation (inactive 
enzyme) of kinase (see below in section 3.2.1. Inhibitors Targeting ATP-Site of 
PKs). The beginning of activation segment includes conserved DFG motif, 
where the first aspartate is directed into the ATP-pocket and coordinates Mg2+, 
which, in turn, coordinates the β- and γ-phosphates of ATP (Mg2+-binding seg-
ment in PKA is 184DFGFA188). The γ-phosphate is additionally coordinated via 
interaction of conserved Lys (Lys168 in PKA) of the catalytic loop (Figure 2). 
Moreover, the residues at the end part of this segment (199CGTP202 in PKA) 
position the phosphorytable Ser/Thr residue of the substrate. Generally, the end 
sequence of activation segment is conserved APE, where the final glutamate 
forms catalytically important salt bridge with arginine (Glu208 and Arg280 in 
PKA).4 Also, all PKs contain a catalytically important aspartate residue (Asp166 
in PKA) in the catalytic loop, which weakens the bond between the oxygen and 
hydrogen atoms of the hydroxyl group of the side chain of phophorylatable 
residue, hence making the oxygen more nucleophilic (Figure 2). In this way, 
Asp166 enables the nucleophilic attack of the oxygen of side-chain of substrate 
onto the γ-phosphorus of MgATP. The 2´ and 3´-hydroxyl groups of ribose 
moiety develop H-bonds with glutamates in the catalytic loop (Glu127 and 
Glu170 in PKA) (Figure 2).4,6,14,28–30  
Finally, the extra stabilization of PKs is achieved via conserved hydrophobic 
interactions. First, the N-lobe is additionally stabilized by interactions between 
Thr88 (αC-helix) and Leu116 (β4-strand) in PKA. The kinase domain is further 
stabilized by interactions of Phe102 (αC-β4 loop in the N-lobe) and Gln149 
(αE-helix in the C-lobe). Other hydrophobic interactions involve Trp222, 
Ile250 and Phe238 in the structure of PKA.4 In addition to the previously 
mentioned hydrophobic residues, the catalytic core of PKs is stabilized through 
hydrophobic residues forming conserved hydrophobic spines.31–33 First, the 
regulatory or R-spine is composed of four residues, whereas 2 locate in the C-
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lobe and 2 in the N-lobe. In particular, the first residue is generally His from 
HRD motif of the catalytic loop (replaced by Tyr164 in PKA), the second is 
Phe from the DFG motif of activation segment (Phe185 in PKA), and the final 
two are aliphatic residues from αC-helix and β4-strand (Leu95 and Leu106 in 
PKA, respectively).14,32 Another spine, termed catalytic or C-spine consists of 
eight residues, wherein 2 come from the N-lobe and 6 from the C-lobe (Val57, 
Ala70, Met128, Leu172, Leu173, Ile174, Leu227, Met231 in PKA). Important-
ly, the correct assembly of R-spine is a hallmark of active conformation of 
kinase, whereas the assembly of C-spine after the binding of ATP is essential 




2.1. General Overview of the Cell Cycle and Mitosis 
The cell cycle is an evolutionally conserved and punctually regulated process 
that is required for the growth as well for development of organism. The cell 
cycle starts with the formation of daughter cells from the mother cell and ends 
with the cell division or death. The cell cycle is divided into four phases: G1 
(gap 1), S (synthesis), G2 (gap 2), and M (mitosis) (Figure 3). The first three, 
i.e., G1, S, and G2, together are known as interphase (Figure 3) that is 
responsible for the preparation of cell for the next division. Specifically, the cell 
is growing in phase G1, and the synthesis of mRNA and proteins required for 
replication of DNA takes place; in S phase, DNA replication and centrosome 
duplication occurs; in G2, the quality of DNA replication is checked, the cell 
continues to grow, and protein synthesis is enhanced. A special case of G1 is 
phase G0 (gap 0), here the cells are in the resting state, but due to external 
growth factors they can re-enter into phase G1. Alternatively, the cells may also 




Figure 3. Phases of the cell cycle of eukaryotic cell. ‘M’ stands for mitosis, red hand 
images stand for checkpoints.  
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During the mitosis, the previously synthesized DNA, organelles and cytoplasm 
are divided between the two daughter cells. Mitosis is further divided into four 
phases: prophase, metaphase, anaphase, and telophase together with cytokinesis 
(Figure 4).34,35 In the first phase, prophase, the chromosomes condence and 
hence become visible through a transmitted light microscope. Subsequently, the 
two centrosomes move to the opposite poles of the cell and the mitotic spindle 
starts to form.34 Mitotic spindle is a dynamic cell structure that is mainly formed 
from microtubules and is essential for chromosome segregation.36 Then, at the 
beginning of metaphase, the nuclear membrane disappears, and the micro-
tubules of mitotic spindle can associate with sister chromatids. Thereafter, the 
chromosomes are aligned to the middle plane of the cell by the interplay of 
forces originating from the mitotic spindle and the chromosomal centromeres. 
In anaphase, the sister chromatids are allocated to the opposite poles. The last 
phase of mitosis is telophase together with cytokinesis, during which the 
cleavage furrow of cell membrane is formed together with the formation of new 
nuclear envelopes around the separated sister chromatids. Finally, the mitotic 
cell divides into two daughter cells, whereas each of the latter contains a full set 
of chromosomes and one centrosome.34 
As the cell cycle is a crucial process for the cell, it requires a precise control 
by checkpoints at the certain timepoints of the cycle. The regulation and func-
tioning of checkpoints are carried out via the signalling cascades of proteins. 
This control mechanism detects and, when possible,  repairs the defects which 
are arisen during the cycle, or the cell is sent to the programmed cell death 
(apoptosis) or cellular senescence (cellular state where the cells cease to 
divide).34,35 First, before the cell is ready to enter the S phase, it must pass the 
G1/S checkpoint which ensures that the cellular ‘machinery’ is prepared for the 
DNA replication and DNA is not defective or damaged; otherwise, the entry to 
the S phase is delayed until the damage is removed, or the cell is sent to 
apoptosis. Next, the intra-S checkpoint slows down the replication of DNA in 
order to minimilize the risk of synthesis errors. Before the M phase, the cell 
must undergo the G2/M checkpoint, which controls the success of DNA repli-
cation and checks the readiness for mitosis. The spindle assembly checkpoint 
(SAC; also known as mitotic checkpoint) in metaphase controls the correct 
assembly of spindle and ensures that the chromosomes are suitably attached to 
microtubules of spindle via kinetochores, hence ensuring the fidelity of chromo-
some segregation to generate identical daughter cells.35–37 The defects in the 
regulation of checkpoints lead to the genetic damage and uncontrollable cell 






2.2. Mitotic Protein Kinases 
The protein signalling cascades that regulate mitotic events transfer the signal 
mainly through phosphorylation of proteins (i.e., functioning of mitotic PKs) 
and protein-protein interactions (PPIs). Thus, the mitotic events are regulated by 
crosstalk of different mitotic PKs.36,38 The collaboration of mitotic PKs triggers 
the comprehensive reorganization of cellular structures, covering the chromo-
some function, spindle assembly, chromosome segregation, and cytokinesis.38–40 
The main PKs that orchestrate mitosis are the following: cyclin-dependent PKs 
(Cdks), Polo-like PKs (Plks), Aurora PKs, and Never-in-mitosis-A-related PKs 
(NIMAs) (Figure 4). The relatively new players in control of mitotic events 
include Haspin (Gsg2) and Greatwall (MAST-L).36,39,40  
 
 




The activity of PKs is spatiotemporally regulated by post-translational modi-
fications (i.e., autophosphorylation or phosphorylation by upstream PKs, or 
ubiquitination which leads to the degradation of protein) or PPIs (that alter the 
activity as well as the cellular location of PKs).36,38 However, differently from 
the other ePKs, mitotic PKs often have a divergent highly conserved motif(s) in 
the activation core (e.g., HRD or DFG motif), which may also point to the 
unusual mechanisms of regulation of their activity.36 
Indeed, since the normal regulation of mitosis is crucial for normal func-
tioning of the cell, the elevated level of mitotic PKs can serve as cancer bio-
markers, as the cancer cells have a faster life cycle and the cells divide un-
controllably.35,38 Therefore, the compounds which are able to identify and 
down-regulate the elevated activity of mitotic PKs are of great interest for 
diagnosis and treatment of related diseases, especially in cancer.35,38 In the 
following paragraphs, the features and functions of Haspin, which is stated to be 








Haploid germ-cell-specific nuclear protein kinase (Haspin; also known as germ 
cell-specific gene 2 protein or Gsg2; molecular weight of human Haspin is 
88,495 Da, it comprises 798 residues41) is a basophilic Ser/Thr PK and plays a 
critical role in the normal progression of mitosis by regulating the behaviour of 
chromosomes during the cell division.42 Haspin is encoded by the germ-cell 
specific gene-2. It was first identified in mice.43,44 The further genomic analysis 
has revealed that Haspin is expressed in many eukaryotic organisms, including 
yeasts, microsporidia, plants, nematodes, flies, fish, amphibians, and mammals. 
Thereby, the C-teminal lobe where the catalytic domain locates, is more 
conserved among the species than the N-lobe.41,42,45–47 In humans, the expres-
sion level of the protein is the highest in testis (in particular in round sper-
matids), but Haspin is abundant in all haploid as well as diploid proliferating 
somatic cells, including thymus, bone marrow and variety of fetal tissues.42,45,48  
Haspin belongs to the group of atypical PKs as it has distinctive catalytic 
core compared to the canonical ePKs. Haspin lacks several highly conserved 
structural features generally required for catalysis, but also contains some spe-
cial structural inserts (discussed below). Furthermore, it has low sequence ho-
mology to other ePKs; hence, it was initially presumed that Haspin is an in-
active pseudokinase. However, the catalytic activity of Haspin was demon-
strated in assays with histone H3 (H3), which was phosphorylated by Haspin at 
Thr3, To date, this protein remains the only well-established physiological sub-
strate of Haspin.48–50 In addition to this site, H3 is phosphorylated at many sites 
during mitosis, including Ser10, Thr11, and Ser28, whereas the phosphorylation 
of Ser10 by mitotic kinase Aurora B is the best known.48 H3 together with H2B, 
H2A and H4 form the nucleosomal octamers around which the DNA is orderly 
packed. The posttranslational modifications of these histones have crucial roles 
in the regulation of control of chromatin structure, which, in turn, is one of the 
central processes of cell division. Therefore, not surprisingly, the histones are 
important targets of PKs that orchestrate mitosis.49 H3 is phosphorylated by 
Haspin during prophase and dephosphorylated by PP1γ in anaphase (see 
below).41 Notably, the methylation of Arg2 and trimethylation of Lys4 of H3 
affect the affinity of H3 towards Haspin due to the bulkiness of methylated 
residues. As a result, the correspondingly modified H3 is not suitable for 
binding to the narrow substrate site of Haspin and hence the catalytic activity of 
Haspin is regulated by epigenetic modification of its substrate.50,51 The 
distinctive structural features of Haspin as well as its activation and pathways 





2.2.2. Comparison of Crystal Structures of  
Catalytical Domains of Haspin and PKA 
Analogously to other ePKs, Haspin has a bilobal structure consisting of a small 
N-terminal lobe and a large C-lobe. As mentioned above, the activation segment 
of ePKs typically consists of ca 35 residues located between the conserved DFG 
and APE motifs. In particular, it contains ATP/Mg2+ binding DFG motif, short 
β-strand (β9), activation loop, and P+1 loop. Generally, the unphosphorylated 
activation loop is disordered or fixed to inactive conformation and, when 
required, the phosphorylation stabilizes the loop appropriately for substrate 
binding. However, Haspin is featured with variety of unusual structural frag-
ments and inserts that form an atypical catalytic core (Figure 5).  
 
 
Figure 5. A) Overlay of co-crystal structures of Haspin kinase domain with AMP (PDB 
3DLZ) and histone H3(1-7) (PDB 4OUC). PK is shown as a cartoon; AMP and histone 
H3(1-7) are presented in ball-and-stick mode and surrounded by green and cyan circles, 
respectively. The G-rich loop is coloured black and activation segment dark blue. B) 
Electrostatic surface potential of kinase domain of Haspin (PDB 2VUW). Electronega-
tive and electropositive areas are shown with red and blue colour, respectively. 
 
 
The comparison of catalytically important residues/motifs of Haspin and PKA 
C discussed in the following text is given in Table 1. First, the highly conserved 
ATP/Mg2+ binding DFG motif (Asp-Phe-Gly) of ePKs is replaced by DYT 
(Asp-Tyr-Thr). Second, the APE motif (Ala-Pro-Glu; generally locating at the 
C-terminus of activation segment) and P+1 loop are absent and replaced by a 
large helical insert (αAS; AAs Gln718 to Lys727) (Figure 6). Third, there is 






aromatic residues. Moreover, the Arg648 in HRD motif (His-Arg-Asp) forms 
hydrogen bonds with the residues Trp733 and Glu735 locating at the tip of the 
activation segment, whereas generally the arginine of HRD interacts with 
phosphates of ATP.50,52 In the upper lobe of Haspin, there is an additional 
helical insert (upper lobe helix or α-ulH; AAs Tyr569 to Phe593). While 
usually the P-loop (G-rich loop (conserved glycines in Haspin 491, 493, 496 
and PKA 50, 52, 55) is highly mobile, in Haspin it is stabilized via polar inter-
actions of α-ulH, i.e., Lys489, Glu492, Asn588.50,53 Also, the α-ulH may have 
the function to regulate the activity of Haspin by binding to the N-terminal tail 
of Haspin and sterically hinder the binding of substrates and thus regulating the 
activity of Haspin.50 Next, the C-lobe contains a β-hairpin insert, which is stabi-
lizing the active conformation of αC-helix, but, at the same time, the C-lobe 
lacks αG-helix. Overall, the activation segment of Haspin is well-structured and 
adopts open but stable conformation, which presumably points to the constitu-




Figure 6. A) Structural features of Haspin on example of co-crystal structure of the 
kinase domain of Haspin with AMP (PDB 3DLZ). PK is shown as a cartoon; AMP is 
presented in ball-and-stick mode (C atoms cyan, O atoms red, N atoms blue, P atoms 
orange). α-ulH is coloured red, β-hairpin insertion magenta, αAS helix orange, β9´ sheet 
dark blue, and αC-helix yellow. B) Rotated view of A). 
 
As other ePKs, ATP-binding pocket is a narrow groove between the two 
lobes.50 The KM values of ATP towards full-length and trunctated kinase domain 
of Haspin are given in Table 2. The adenine ring of ATP is bound to the hydro-
phobic cleft locating between the lobes. The N1 and N6 amino groups of 











analogous interaction with Glu121 and Val123 in PKA co-crystal structure with 
ATP) (Figure 7). The hydroxyl groups of ribose moiety give interactions with 
Asp611 (Glu127 in PKA), whereas 3´-hydroxyl additionally interacts with 
Gly653 (Glu170 in PKA). Furthermore, the α-phosphate of nucleotide is co-
ordinated via conserved Lys511 (Lys72 in PKA) and, at the same time, Lys511 
forms the salt bridge with Glu535 of αC-helix (the latter is a hallmark of active 
kinase, as discussed above).50 Next, in Ser/Thr PKs γ-phosphate forms a charge-
reinforced hydrogen bond with highly conserved Lys (Lys168 in PKA, which 
interacts with γ-phosphate of ATP, aspartate of HRD, activation loop and sub-
strate peptide), and this interaction is required for phosphoryl transfer. How-
ever, in Haspin the function of conserved Lys is fulfilled by His651.47,50  
 
 
Table 1. Summarizing table of important residues/motifs of Haspin and PKA C 
discussed in text (PDB 4OUC, 1ATP) 
 Haspin PKA C 
G-rich loop (GxGxΦG) 491GEGVFG496 50GTGSFG55, 
DFG  687DYT696 184DYT186 
Y/HRD 647HRD649 164YRD166 
APE - (αAS: Gln718 to Lys727) 206-208 
β3-Lys – αC-Glu pair Lys511 – Glu535 Lys72 – Glu91 
Activation segment 687-726 184-208 
N1 and N6 amino groups of 
adenosine moiety Glu606 and Glu608 Glu121 and Val123 
Hydroxyl groups of ribose moiety Asp611 Gly653 
Glu127 
Glu170 
α-phosphate of nucleotide Lys511 Lys72 
Intracatalytic loop salt bridge Asp649 – His651 Asp166 – Lys168 
 
 
In addition to the previously mentioned polar contacts, the nucleotide ring 
system is stabilized by hydrophobic and π-π interactions with aromatic AAs of 
Haspin (e.g., Phe607, Tyr688, Trp652, Val704, Leu710, Phe719, Tyr722, 
Trp733).50,52 Notably, in Haspin structure there is no Mg2+ binding site in 
vicinity of DYT motif; however, a Mg2+ ion is coordinated by Asp716, Gln718, 
Trp652, and Tyr747 in the interface of catalytic loop. Therefore, it is suggested 







Figure 7. Comparison of interactions of nucleosidic molecule bound to ATP-site of 
Haspin or PKA C. A) Co-crystal structure of kinase domain of Haspin with AMP (PDB 
3IQ7, 3DLZ). PK is shown as magenta (PDB 3DLZ) and blue (PDB 3IQ7) cartoon. B) 
Co-crystal structure of PKA C with ATP (PDB 1ATP). PK is shown as orange cartoon. 
Residues of PKs forming interactions with the co-crystallized small molecules are 
shown as lines and are labelled; hydrogen bonds are shows as black dotted lines. Mn2+-
ions are shown as magenta circles (note: no electron density can be observed for Mg2+-
ion(s) near ATP-site in co-crystal of Haspin with AMP). 
 
 
The substrate-binding site of Haspin is located on the surface of the C-lobe. The 
KM values of H3 peptide towards full-length and trunctated kinase domain of 
Haspin are given in Table 2. As the activation segment contains several acidic 
AAs (Asp707, Glu708, Asp709) but lacks P+1 loop and APE motif, it leads to 
the formation of the highly negatively charged narrow substrate-binding loop. 
In this way, the substrate pocket of Haspin is ideally suited for binding of basic 
N-terminal tale of H3 (Figure 5).48–50 The co-crystal structure of Haspin with N-
terminal peptide of histone H3(1-7) [H3(1-7)] revealed a unique U-turn shape 
binding mode of histone peptide (sharp ca 180° turn at Lys4) when positioned to 
Haspin (Figure 8). Such binding mode is distinct from substrates of other PKs 
(e.g., PKI(5-24) as an analogue of substrate of PKA C, Figure 8). In particular, 
Lys4 is positioned into pocket lined by kinase residues that develop hydro-
phobic interactions (Leu690, Val704, Leu710) as well as charge-reinforced 
hydrogen bonds (Asp707, Asp709) to the alkyl chain and amine group of Lys4, 
respectively. Moreover, Gln5 forms hydrogen bond with Asp714 and Thr6 flips 
back over Arg2. Next, Ala1 (H-bonded with Glu613) and Thr3 (H-bonded with 
Asp649 and Gln718) are directed inside the substrate binding cleft. Arg2 is 
located in the relatively deep hydrophobic pockets of the N-terminal lobe 
formed between the two loops of the kinase (Val494 from the G-rich loop and 
Ala587 from the loop preceding α-uIH helix). However, the side-chain of Arg2 
protrudes to the N-lobe, while its guanidine group and the carboxyl oxygen 





Figure 8. Comparison of substrate-sites of Haspin and PKA C. A) Co-crystal structure 
of Haspin with H3(1-7) (PDB 4OUC). B) Co-crystal structure of PKA C with ATP and 
PKI(5-24) (PDB 1ATP). PKs are shown as cartoons; ATP is depicted in ball-and-sticks 
mode (C atoms cyan, O atoms red, N atoms blue, P atoms orange); H3(1-7) and PKI(5-
24) are shown as sticks; residues of peptides are shown in Italic [note: in case of PKI(5-
24) only Thr5, Asp24 and Ala21 are marked for clarity]; the locations corresponding to 
phosphorylatable residues are indicated with black arrows [note: in case of PKI(5-24) 
the phosphorylatable residue is replaced with Ala (i.e., Ala21)]; residues of PKs forming 
interactions with the co-crystallized peptides are labelled and shown as lines; hydrogen 
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app – apparent Michaelis-Menten constant; ND – not determined; His6 – hexahistidine 












The reported consensus sequence of Haspin substrates is Ala/Val-Arg-Ser/Thr-
Lys-(X-noAsp/Glu), where Ser/Thr denotes the phosphorylatable residue and X 
corresponds to any AA except Asp or Glu54 (for comparison: the consensus 
sequence of substrates of PKA is Arg–Arg/Lys–X–Ser/Thr-Leu/Ile58). Based on 
this, the sequence of N-terminal tail of H3 is in complete agreement with the 
key consensus sequence of Haspin. Notably, based on the aforementioned con-
sensus sequence, their location in mitotic cells and the supporting mass spectro-
metric studies, the centromere protein T (CENP-T; AAs Thr14/27/57 and 
Ser72) and histone H2A (Thr16) are also possible substrates of Haspin.54 Re-
cently, Hada and co-workers have demonstrated that Haspin was responsible for 
phosphorylation of TH2A (germ cell-specific variant of H2A) at Thr127 in 
vivo.59 
 
2.2.3. Regulation of Haspin Activity and  
The Role of Haspin in Cellular Pathways 
In agreement with the aforementioned Haspin-catalyzed phosphorylation of 
Thr3 of H3 (H3T3), it has been reported that the application of siRNA of 
Haspin leads to the decrease of phosphorylation of H3T3. Moreover, the 
depletion causes delocalization of cohesin and the members of chromosomal 
passenger complex (CPC; discussed below) from centromeres, increased 
amount of monoorientated sister chromatid pairs, misalignment of chromo-
somes in metaphase, the activation of SAC, and mitotic arrest.48,49,60–62 On the 
other hand, the overexpression of Haspin causes increased stabilization of 
chromosome arm cohesion, abnormal dissociation of sister chromosomes, and 
mitotic delay before anaphase. Besides, in case of overexpression of Haspin, 
phospho-Thr3 of H3 (pH3T3) is detectable throughout the cell cycle, whereas 
normally it is only detectable between the late G2 and anaphase.48,49,63,64 
Surprisingly, the experiments with Haspin knock-out mice have shown the 
normal fenotype as well as fertility of animals; however, the lack of Haspin may 
be balanced by other, but to date still unknown mechanisms.65  
As previously discussed, large number of ePKs require (auto)phospho-
rylation of the activation loop to obtain the catalytic activity. However, in case 
of Haspin this regulation mechanism is unlikely as in the co-crystal of catalytic 
domain, the activation segment is structured by the surrounding interactions 
(e.g., salt bridge, hydrophobic interactions) and hence is in constitutively active 
conformation.50,52 Human Haspin is expressed nearly on a constant level 
throughout the cell cycle, but its activity peaks in mitosis.48,50 In interphase, 
Haspin is found in nuclei and during mitosis it is located to condensed chromo-
somes throughout the process, to the centromeres during nuclear envelope 
breakdown, to spindle microtubules in metaphase, and to the midbody in telo-
phase.49 Overall, in early mitosis Haspin becomes associated with condensed 
chromosomes and is mainly concentrated in central regions, but also locates 
along the chromosomal arms in smaller amounts.49 Such ‘traveling’ of Haspin 
during the cell cycle is associated with the sister chromatid cohesion protein 
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Pds5, through which Haspin is recruited to centromeric chromatin.66,67 As pre-
viously mentioned, H3T3 is phosphorylated at the beginning of mitosis (during 
prophase) and dephosphorylated in anaphase.41 If Haspin is constitutively 
active, the molecular mechanism that temporarily restricts the appearance of 
pH3T3 just to mitosis is still unclear. In the following text, a brief overview of 
the present knowledge is introduced. 
Ghenoiu and co-workers proposed that the activity of Haspin is autoinhibited 
in interphase by a basic inhibitory segment next to the kinase domain. The inter-
ruption of autoinhibition of Haspin is initiated by a priming phosphorylation of 
the N-terminal domain by cyclin-dependent PK type 1 (Cdk1; activated by 
cyclin B upon entry to mitosis), following the recruitment of Polo-like kinase 
(Plk1), which, in turn, mediates the further abundant phosphorylation of N-lobe 
at multiple sites. Consequently, the basic inhibitory segment of the N-lobe is 
unfolded from the C-lobe and hence the steric blocking of catalytic core is 
removed. Thereafter, Haspin is able to achieve its full catalytic activity.68 
Nevertheless, this hypothesis does not explain why the overexpressed Haspin 
phosphorylates H3T3 at each stage of the cell cycle, and why the recombinant 
full-length Haspin is featured with catalytic activity. However, the latter pheno-
menon may be, in turn, affected by possible impact of affinity tags on the inter-
actions between the N- and C-termini.  
The second theory suggests that the N-terminal domain of Haspin is directly 
phosphorylated by mitotic kinase Aurora B. At the same time, Aurora B-me-
diated phosphorylation does not influence the activity of recombinant Haspin in 
vitro, but leads to the increase of level of pH3T3 in cells. It has been proposed 
that such outcome is achieved 1) by displacing an unknown inhibitory protein, 
which binds to Haspin in interphase, or 2) by enabling the access of Haspin to 
nucleosomal H3 in cells.62 Aurora B is a Ser/Thr PK that is a key player in 
mitosis and mediates the chromosome attachment to spindle. Also, it has an 
outstanding role in pathways of Haspin (Figure 9).  
In particular, Aurora B is a member of CPC, which also incorporates the 
Inner Centromere Protein (INCENP), Borealin and Survivin.69,70 The locali-
zation of CPC changes throughout the cell cycle, whereas its correct locali-
zation ensures the spatiotemporal control of phosphorylation of substrates in-
volved in the repair of errors of interactions between chromosomes and micro-
tubules, activation of SAC, and regulation of contractile mechanisms that lead 
to cytokinesis.69 Haspin starts to phosphorylate H3T3 in late G2/early prophase, 
whereas in late prophase pH3T3 is spread along the chromosome arms.63,70,71 
The phosphorylation of H3 at Ser10 (pH3S10) catalysed by Aurora B disrupts 
interaction of the heterochromatin protein 1 (HP1) with H3 and dispelles HP1 
from chromatin (Figure 9). Consequently, H3 is released and H3T3 phospho-
rylation by Haspin is favoured.70,72 Next, the pH3T3 binds to Survivin leading to 
the recruitment of CPC to centromere.61,70,73 Furthermore, the CPC localization 
to centromere is facilitated by interaction with Shugoshin via Borealine, 
whereas the latter binds the histone H2A which is phosphorylated at Thr120 by 




the phosphorylation of Haspin by Aurora B acts as a positive feedback loop by 




Figure 9. Illustrative scheme of Haspin-involving pathways in prometaphase/metaphase. 
Normal arrow indicates activation, enhancement, facilitation of interaction; blunt-ended 
arrow indicates inactivation or depletion; dashed arrow indicates recruitment. 
 
 
Then, during the transition to prometaphase, the pH3T3 disappears from the 
chromosome arms and concentrates to the inner centromeres due to the phos-
phatase activity: dephosphorylation of pH3T3 is regulated by protein phos-
phatase PP1γ including its regulatory subunit Repo-Man.66,70,75 Repo-Man is, in 
turn, phosphorylated by Aurora B; this phosphorylation inactivates Repo-Man 
in close proximity to Aurora B pool, prevents chromosomal localization of 
Repo-Man and hence contributes to increase of level of pH3T3.70,76 Moreover, 
Repo-Man interacts with phosphatase PP2A and thereby can locally reverse 
Aurora B action by allowing the removal of pH3T3 from chromosome arms 
during prometaphase.70,76 Overall, the intersection of Haspin, Aurora B and 
phosphatase pathways regulate the level of pH3T3 and allow the enrichment of 
pH3T3 as well as CPC at the inner centromeres, thus ensuring the fidelity of 
progression of mitosis (Figure 9).74  
Finally, when the criteria of SAC are passed, the cell is ready to enter 
anaphase. Thereby, the cell division control protein 20 (Cdc20) activates the 
proteases that degradate different proteins, including cyclin B (activates Cdk1, 
see above), hence changing the ensemble of intracellular proteins – and before 




3. Inhibitors of Protein Kinases 
3.1. General Characteristics 
An inhibitor of enzyme is a compound which binds to the enzyme, such as PK, 
and thereby disables the enzymatic catalysis by preventing the binding of  
(co-)substrates and/or changing the 3D-structure of enzyme. The inhibitors of 
enzyme are applied in vitro as well as in vivo assays to reduce the activity of 
enzymes and look into the function and signalling pathways of biological cata-
lysts. Furthermore, inhibitors are used to quantify the amount of different en-
zymes in biochemical assays or in natural milieu.77 Nevertheless, when using 
inhibitors in vivo assays, it must be taken into consideration that the potency 
(expressed as Ki or IC50 value1) as well as selectivity of inhibitor may be re-
markably affected by different factors, e.g., the cell plasma membrane-penetra-
tive properties or intracellular stability of inhibitor.78 Inhibitors are divided into 
different classes based on the origin (natural or synthetic), binding character 
(reversible or irreversible), mechanism of binding relative to (co-)substrates of 
enzyme (competitive, uncompetitive or semicompetitive), and positioning of 
inhibitor in the complex with enzyme (types I–V).77 
 
 
3.2. Classes of Inhibitors of Protein Kinases 
In inhibitor development, there are two directions, first, to develop an inhibitor 
with a relatively wide selectivity profile targeting a specific family of PKs; 
second, to develop an inhibitor with narrow selectivity profile possessing high 
affinity against a specific family member. There is no overall consensus about 
the acceptable level of selectivity, however, Parang and Sun stated that the 
selective inhibitor should exhibit at least 100-fold selectivity towards desired 
target over other kinases.79 Still, even when the inhibitor shows high selectivity 
towards a panel of PKs in biochemical assays, its is not guaranteed that the 
inhibitor is maintaining its selectivity properties in cellular environment with 
high complexity.79   
As PKs catalyse the phosphorylation reaction, binding of both the phospho-
ryl group donor ATP as well as the acceptor substrate protein to the enzyme is 
required for the reaction to occur. There are different strategies in inhibitor 
design and development to block or reduce the extent of phosphorylation 
reaction catalysed by PKs. A frequently used classification is based on the site 
that the inhibitor is targeting: ATP-binding pocket, substrate-binding pocket, or 
both simultaneously (bisubstrate inhibitors). Also, inhibitors that bind outside 
the canonical catalytic core of the PK (allosteric inhibitors) have emerged, 
                                                 
1  IC50 value is A) the concentration of inhibitor at which the  rate of phosphorylation 
reaction is half of maximum (in inhibition assays), or B) the concentration of competitor at 
which the amount of complex of fluorescent probe and kinase is half of maximum (in 
binding assays).  
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which change the conformation of PK and thereby counteract the binding of 
substrates.4,79,80 Another classification of PK inhibitors that groups them to 
types I – V is based on positioning of the inhibitor in complex with the enzyme 
(Table 3).1,4,78,80–82 As mentioned above, 39 small-molecule inhibitors of PKs 
targeting one or multible kinases are approved by FDA for clinical use.1,2 In the 
following paragraphs, the properties of ATP-site binding inhibitors, substrate-
binding site inhibitors, and bisubstrate-analogue inhibitors are discussed. 
 
 
Table 3. Classification of inhibitors based on the structure of enzyme-inhibitor complex 
Type of 
Inhibitor Binding Features 
Reversibility 
(+/-) 
Type I Inhibitor binds to ATP-pocket of active conformation of PK + 
Type I ½  Inhibitor binds to ATP-pocket of inactive conformation of PK (DFG in) + 
Type II Inhibitor binds to ATP-pocket of inactive conformation of PK (DFG out) + 
Type III Inhibitor binds to site next to ATP-pocket (allosteric inhibitor) + 
Type IV Inhibitor binds far away from ATP-pocket (allosteric inhibitor) + 
Type V Inhibitor occupies 2 sites (bivalent inhibitor) + 
 
3.2.1. Inhibitors Targeting ATP-Site of PKs 
ATP-binding cleft is located between the two catalytic lobes and during the 
binding of ATP to PK, two nitrogen atoms of adenine moiety of ATP form 
hydrogen bonds with the hinge backbone residues (Figure 2, Figure 7). The 
similar binding mode is generally maintained in the structure of ATP-mimetic 
inhibitors.4,16,79 The targeting of ATP-pocket of PKs in cellular environment was 
first successfully demonstrated by ATP-competiting inhibitors, e.g., staurospo-
rine and H89 (Figure 10), and to date the majority of inhibitors of PKs deve-
loped are targeting ATP-binding site of PKs.4,7,83 Still, as the ATP-binding 
pocket is relatively highly conserved among PKs that share a large portion of 
common sequence and structural homology, it was initially presumed that 
design of the selective ATP-mimetic inhibitors is challenging or rather im-
possible.6 Additionally, the efficiency of ATP-mimetic inhibitors is decreased in 
situ due to their competion with high intracellular concentration of ATP (2– 
10 mM).79 However, the discovery and approval of clinical use of imatinib 
(Gleevec, STI-571; Figure 10) in 2001 for the treatment of chronic myelo-
genous leukemia paved the road for the development of selective ATP-site 
inhibitors.84 Nevertheless, in oncology the exposure of ATP-site targeting drugs 
may lead to mutations in ATP-pocket which can either render binding of ATP 
more effective, or sterically preclude binding of inhibitors. This situation is 
called ‘acquired drug resistance’, in which case the tumor initially shrinks in 
response to the exposure of drug, but eventually starts to increase again.4,55,85,86 
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The tumor resistant to one drug might, however, lack resistance to another drug 
targeting the same oncogenic kinase – therefore, the development of novel 




Figure 10. Structures of adenosine (A), 5-iodotubercidin (B), staurosporine (C), H89 
(D), and imatinib (E). 
 
 
The first crystal structure of the active site of a PK (PKA C) was published in 
1991.21 Now, in total, more than half of the kinome is covered by the available 
crystal structures87,88 that has revealed the structural diversity of the members of 
the superfamily of PKs. This knowledge has driven to the structure-guided 
construction of PK inhibitors. Several regions of PKs, especially the hydro-
phobic regions adjacent to ATP-binding cleft and the essential gatekeeper resi-
due of ATP-pocket, can be exploited to achieve the selectivity of ATP-mimetic 
inhibitors.4,80  
The gatekeeper key residue locates near the hinge connecting the large and 
small lobes of kinase and closes the access to the hydrophobic ‘back pocket’ of 
ATP site. The size of side chain of this AA is crucial: the smaller the residue, 
the larger the size and higher the accessibility to the hydrophobic pocket behind 
the ATP-site. Relatively small gatekeeper residue (e.g., Gly, Ala, Ser) results in 
more spacious ATP-binding site and provides access to the rear part of hydro-
phobic pocket. On the other hand, when the gatekeeper residue is AA with a large 
side chain (Phe, Tyr), the accessibility of inhibitors is largely restricted.4,80  
It is also possible to target the different conformational forms of certain PKs, 
i.e., the active or inactive forms of PK. One of the important differences 
between these two states is the rearrangement of highly conserved DFG motif 
required for the binding of ATP/Mg2+. In particular, the active form is generally 
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well-characterized and its structure is similar among PKs. As a result of phos-
phorylation of regulative Ser, Thr or Tyr residues, DFG motif is rotated to its 
‘in’ = ‘open’ conformation. In active conformation of PK, the side chain of 
aspartate residue of DFG motif is directed into the ATP-pocket and coordinates 
Mg2+ together with allowing the binding of peptide/protein substrate. Further-
more, the active conformation is usually relatively rigid, which is required to 
enable the exact positioning of catalytically important residues. This feature is 
also used to design the compounds which securely fit into the more rigid ATP-
pocket (type I inhibitors, see above). In inactive conformation of PK, DFG 
motif is roted by approximatly 180 degrees (DFG ‘out’ = ‘closed’) resulting in 
closed conformation of the activation loop and formation of additional binding 
pocket adjacent to ATP-site.4,79,80 
Initially, it was assumed that the DFG ‘out’ conformation is unique for 
certain PKs and the compounds targeting the surrounding binding pocket of 
ATP-site (type II inhibtors, see above) are endowed with increased selectivity. 
However, it has been recently concluded that the inactive conformation of PKs 
can be targeted by different scaffolds, which probably reflects high dynamics of 
binding pocket; therefore, type II inhibitors may not offer a clear advantage 
over type I inhibitors in the development of highly selective compounds.80,89 
Development of inhibitors for Haspin has not been considerably intense, but 
some successful efforts have been disclosed. Most Haspin targeting inhibitors 
are directed to the ATP-binding site. The most well-known inhibitor for Haspin 
is 5-iodotubercidin (5-ITu), which was, however, initially identified both as an 
inhibitor (IC50 = 26 nM) and a substrate for adenosine kinase (ADK) (see below 
in section 5. PK Selectivity of Itc-Incorporating Conjugate [Paper III: Kestav et 
al., 2017]). 90–92 Other Haspin-targeting ATP-site inhibitors include β-carboline 




3.2.2. Inhibitors Targeting Substrate-Binding Site of PKs 
Indeed, as the ATP-pocket is conserved among proteins of the superfamily of 
PKs, another strategy of inhibitor development is targeting of the substrate-
binding site of PK – as the interactions between the kinase and substrate should 
vary considerably among different kinases. One strategy is to use peptides or 
peptidomimetics, which compete with substrate and disrupt protein-protein 
interactions (PPIs).94 As PKs phosphorylate the substrates incorporating a 
certain amino acid sequence (so-called key sequence or consensus sequence, see 
above), therefore, peptides and their analogues imitating the substrates can 
serve as substrate-competive inhibitors.95,96  
The inhibitors targeting substrate binding site of PKs may have an advantage 
over ATP-mimetics, since the intracellular concentration of protein substrate is 
remarkably lower compared to the concentration of ATP.6,79 On the other hand, 
the substrate binding site of PKs occupies larger area than ATP-site, sometimes 
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including the grooves on the surface of both, N- and C-teminal lobes of PK. 
Therefore, to achieve the high affinity, the inhibitor must be sufficiently large as 
the generated interactions must compensate the energy loss resulting from the 
removal of structured water layer on the surface of PK. This is a significant 
shortcoming, as the large molecules often lack the plasma membrane-pene-
trating properties and the natural substrate imitating peptides are often unstable 
against the proteolytic degradation in cellular environment.58,95 However, the 
stability of peptides can be remarkably improved by using peptidomimetics 
containing non-proteinogenic AAs or D-amino acids, as well as compounds 
with altered backbone.97–99 
One of the first discovered substrate-site binding inhibitors is thermo-stable 
protein kinase inhibitor peptide or PKI (molecular weight of full length murine 
PKI is 8 kDa; three isoforms α/β/γ), which is a natural inhibitor of PKA (Ki 
value of PKIα is 0.2 nM).100,101 PKI includes the sequence of Arg-Arg-Asp-Ala-
Leu, resembling the key sequence of substrates of PKA (Arg–Arg/Lys–X–
Ser/Thr-Leu/Ile, where X corresponds to any AA).58,100 The high affinity of PKI 
towards PKA is also attributed to the amphiphatic helix that precedes the 
consensus site, i.e., locates in the N-terminal of consensus sequence.102 
 
 
3.2.3. Bisubstrate Inhibitors 
Bisubstrate inhibitors contain two fragments which are covalently linked by a 
linker, whereas one fragment binds to the ATP-pocket and another to the 
substrate-binding site. The development of bisubstrate inhibitors is based on the 
concept that the fragments of inhibitor bind to distinct but still adjacent pockets 
in the active core of enzyme. As a result of successful design, both fragments 
maintain their interactions with enzyme.79,103 The advantage of bisubstrate 
inhibitors is the synergistic effect compared to the separate components: the free 
energy of binding of bisubstrate inhibitor is the sum of the binding free energies 
of separate fragments together with reduced entropic penalty achieved through 
the interactions of one molecule instead of several fragments with protein.104 
Additionally, the binding of one linked fragment increases the local con-
centration of another fragment near the corresponding binding site and thus 
elevates the probability of binding event. When the two fragments are linked by 
an appropriate linker, the affinity of the obtained conjugate may be around 6 
orders of magnitude higher compared to the individual molecules (i.e., when the 
affinity of individual fragments is at the range of mM, then the suitable linking 
may endow a conjugate with nM range of affinity).79,103,105 However, when the 
length of the linker is not optimal, it precludes simultaneous binding of the 
fragments of conjugate and thus leads to the loss of achieved improvement in 
affinity of bisubstrate-type inhibitors. Furthermore, the linker must be suffi-
ciently long and flexible to maintain the conformational mobility of enzyme-
inhibitor complex.106  
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The bisubstrate nature of inhibitor towards corresponding PK can be con-
firmed mainly by three different methods: 1) evaluation of co-crystal structure 
of inhibitor with PK, 2) kinetic analysis of competiveness of inhibitors versus 
both substrates, and 3) displacement of conjugate from its complex with PK by 
both an ATP-competive inhibitor and substrate-site targeting inhibitor.103 From 
the co-crystal structure of bisubstrate inhibitor with the PK, it is directly pos-
sible to show whether the fragments of conjugate occupy the desired substrate-
binding sites of kinase or not.103,107–109 In kinetic analysis, the inhibition mecha-
nism of bisubstrate inhibitor is determined. For this, the phosphorylation level 
of substrate is monitored, whereas in case of the inhibition pattern of conjugate 
versus ATP is determined, the concentration of ATP is varied, but at the same 
time the concentration of substrate is kept constant and vice versa.110 Diffe-
rently, displacement format of an assay requires labeled form of an inhibitor 
(e.g., using a fluorescent dye) that can then be competitively displaced from its 
complex with the kinase by increasing concentrations of ATP or substrate 
peptide/protein.111,112 
The first bisubstrate inhibitors were developed in 1970s.113,114 These inhi-
bitors were the analogues of transition-states occurring during the transfer of 
phosphoryl group from ATP to substrate: the design was based on the assump-
tion that the transition state complex represents the best geometry leading to the 
decrease of activation energy of catalyzed reaction.103,115 
The approach where a potent ATP-competing inhibitor was incorporated into 
the structure of a bisubstrate inhibitor was first used by research group of A. 
Ricouart in 1991, who linked an isoquinoline sulphonamide-derived ATP-com-
petitive inhibitor H9 (Ki value towards PKA C was 2 μM) with hexa-L-arginine 
peptidic fragment (the peptide alone possessed mM range of affinity) by using 
β-alanine and L-serine in the structure of linker. The Ki value of the resulting 
conjugate towards PKA C was 2 nM.103,116 
The most well-characterized subtype of bisubstrate inhibitors of PKs are 
adenosine analogue-oligoarginine conjugates or ARCs developed by Uri and 
co-workers. The initially developed ARCs were composed of an adenosine 
analogue (a derivative of adenosine, e.g., Adc, or ATP-competitive inhibitor of 
target PK), an oligoarginine peptidic fragment, and hydrophobic linker(s) (Fi-
gure 11).103,117 The oligoarginine fragment in the structure of ARCs was neces-
sary for targeting basophilic PKs. Furthermore, it provided the conjugates with 
properties of arginine-rich cell-penetrating delivery peptides118, thus enabling 
the use of compounds in cellular milieu.119–125 The conjugates incorporating the 
oligoarginine fragment possessed wide selectivity profile, which could be used, 
for instance, for development of relatively generic fluorescent probes applicable 




Figure 11. Structure of ARC shown on the example of ARC-902. 
 
 
The subsequent structural modifications and rational design guided by the co-
crystal structures of ARCs with target PKs108,109,126–128 have led to the re-
markable increase in stability and affinity of compounds, and, at the same time, 
allowed tuning of the selectivity of conjugates towards different PKs. To start 
with, first generation ARCs incorporated L-amino acids in peptidic part, but 
their replacement with D-counterparts improved significantly the stability of 
conjugates for proteolytic degradation.117,121 Next, with the aim to increase the 
selectivity as well as affinity of conjugates towards specific PKs, the chiral spacer 
separating two linkers was introduced into the structure of ARCs.126,127,129 The 
chiral spacer was obligatory to direct the peptidic fragment of conjugate towards 
the substrate-site. Finally, the affinity and selectivity of ARCs was successfully 
tuned by varying the ATP-binding fragment of conjugates with the aim to obtain 
selective compounds (e.g., Fasudil for Rho-kinase) or, vice versa, generic 
conjugates (e.g., H9).121,126,128–132 The most recent development in structures 
ARCs is the replacement of oligoarginine fragment of conjugates with a peptide 
preferred by the specific target PK (e.g., oligoaspartate or oligoaspartate-
imitating peptoid fragment for targeting acidophilic PK CK2).108,130,132 The latter 
principle was also applied within this work, taking into account the peptidic 
preferences of Haspin.   
ARCs have been successfully applied as auxiliary reagents in different bio-
physical and biochemical assays as well as in cellular environment (e.g., live 
cells, cell lysates).111,112,122–125,133–138 The methods utilizing ARCs that were 
applied during this study are discussed in detail in Methods under section 2. 
Biochemical Assays with Detection of Photoluminescence.  
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AIMS OF THE STUDY 
The aims of the current study were the following: 
 biochemical screening of the initial set of ARCs towards Haspin, whereas 
ARCs represented variable structural scaffolds;  
 co-crystallization of Haspin with the most potent conjugates from the initial 
set; 
 rational design of Haspin-selective conjugates and fluorescent probes based 
on the co-crystal structures of Haspin; 
 co-crystallization of novel conjugates with Haspin; 
 determination of kinetic properties of association and dissociation of con-
jugates and fluorescent probes to/from Haspin; 




1. Synthesis of Compounds 
1.1. Solid Phase Peptide Synthesis 
The main principles of solid phase peptide synthesis (SPPS) were first pub-
lished in 1963 by R. B. Merrifield139, who received the Nobel Prize in Che-
mistry in 1984. Initially, the method was used to synthesize ‘classical’ oligo-
peptides on insoluble support, but to date an increasing number of structural 
scaffolds representing the peptide analogues (e.g., peptoids)130,140, oligo-
nucleotides141,142, etc have been assembled by using SPPS.  
The synthesis of peptides is carried out on solid polymeric supports (so-
called resins; e.g., cross-linked polystyrene-divinylbenzene copolymer), which 
must be insoluble when immersed in solvents of synthesis but show good 
swelling properties in these solvents, and, at the same time, be inert to all the 
reactions performed. Usually, aprotonic solvents with an intermediate or low 
polarity are used for coupling reactions (e.g., N,N-dimethylformamide, DMF or 
dichloroethane, DCE). Onto the surface and inside the resin beads, a certain 
amount of reactive groups are introduced onto which the synthesized chain can 
be assembled. The amount of such centres in moles per mass unit of resin is 
termed as loading of resin.143,144 The loading of resin must be as high as possible 
in order to reduce the cost of synthesis. However, too high loading may cause 
the steric hindrance to the growing chain (i.e., synthesized peptide) and hence 
the assessibility of reagents to reaction centres is prevented. This situation is 
leading to the decrease of yield and should whenever possible be avoided by 
keeping the loading optimal in relation to length of the synthesized peptide.  
The peptide synthesis is carried out in the direction from C- to N-terminus. 
In order to facilitate the diffusion of reagents to the reaction centres, spacers or 
peptide linkers are used, elongating the distance between the matrix and the 
reactive groups and also introducing suitable modifications (e.g., amidation) to 
the C-terminus of the synthesized sequence (Figure 12).143 On the other hand, 
the synthesis of peptide libraries in peptide microarrays by using SPPS can also 
be performed right on the microchip plate (i.e., without usage of resin), hence 
allowing the performance of a large amount of parallel syntheses and sub-




































































The steps of ‘classical’ SPPS are as follows. The first amino acid counting from 
the C-terminus of peptide is activated and attached to the resin via its carboxyl 
group; in this way, this AA becomes the first monomer in the growing peptide 
chain (Figure 12). The peptide bond formation is a reaction with high activation 
energy and thus needs the involvement of activators to convert carboxyl group 
to more reactive species (e.g., active esters). The activators (e.g., 2-(1H-benzo-
triazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate or HBTU, 1-
hydroxybenzotriazole or HOBt, N,N'-diisopropylcarbodiimide or DIC) render 
the carboxyl group of added amino acid more electrophilic by pulling electrons 
from it and, consequently, facilitate the nucleophilic attack by the amine group 




Figure 13. Structures of common activators HBTU (A), HOBt (B) and DIC (C). 
 
 
Thereafter, the following steps are performed until the peptide with desired 
length and structure is obtained:  
1.  removal of group protecting the N-terminus of previous AA,  
2.  activation of the C-terminus of added AA, 
3.  coupling of AA (acylation reaction). 
 
Finally, the last step of synthesis is the cleavage of the peptidic chain from the 
resin, usually accompanied by the simultaneous removal of protecting groups of 
the side-chains. In Boc-SPPS, the α-amino group protecting (Nα-protector) Boc-
group is removed by treatment with strong acid, usually with trifluoroacetic 
acid (TFA); hence, the cleavage of peptide must be performed with even 
stronger acid, e.g., HF. Differently, the Fmoc-group is removed from N-termi-
nus of amino acid by treatment with a weak organic base, usually with piperi-
dine, whereas the releasing of final peptide from resin can then be achieved 
using TFA.143,144 
The successful execution of SPPS requires the usage and removal of pro-
tective groups to prevent the undesired side-reactions with a multitude of 
functional groups that AAs can bear. The main role of Nα-protectors is to 
delocalize the free electron pair of the nucleophilic N-terminal amino group 
with the aim to avoid the reaction of the added AA with other molecules in 
solution. The carboxyl group of growing chain is typically attached to the resin 
and does not require special protection prior to the removal of peptide chain 
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from carrier (cleavage). In traditional SPPS, two main synthesis strategies are 
applied based on the Nα-protecting groups used throughout the synthesis: tert-
butoxycarbonyl (Boc) and 9-fluorenylmethoxycarbonyl (Fmoc) (accordingly, 
the synthetic method is termed as Boc-SPPS or Fmoc-SPPS) (Figure 14). While 
Boc-group is removed by strong acid (usually TFA), Fmoc-group can be readily 




Figure 14. Structures of Boc (A), Fmoc (B), ivDde (C) and Mtt (D) protecting groups. 
 
 
In case if the side-chains of AAs contain reactive functional groups, the latter 
must also be protected. In general, the orthogonality rule applies: the groups 
protecting N-terminus and side-chains must be removable under different 
conditions.143 A successful example of application of the orthogonal protecting 
groups in SPPS was used within given thesis during synthesis of conjugates 
targeting Haspin.127,128 Briefly, the H3(1-7)-like peptidic part was synthesized 
by using traditional Fmoc-SPPS; the side chains of other AAs except LLys 
which incorporated 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)isovaleryl 
group (ivDde-group, Figure 14) contained acid-labile protecting groups. Next, 
the N-terminus of the assembled peptidic part was protected with the acid-labile 
Boc-group. Thereafter, the ivDde-group was removed by treatment with 10% 
hydrazine solution in DMF and via the side-chain of Lys, linkers and the 
nucleosidic fragment were introduced to the structure of the conjugate. Then, 4-
methyltrityl (Mtt, Figure 14) group was removed from the side-chain of DLys of 
C-terminus by treatment with the mixture of TFA/triisopropylsilane/dichloro-
methane (1/2/97, v/v/v) and, thereafter, myristic acid moiety (Myr) was linked 
to the structure of conjugate via the side chain of Lys of C-terminal. Finally, the 
conjugate was cleaved from resin using TFA/H2O/triisopropylsilane (90/5/5, 
v/v/v) with simultaneous removal of the protecting groups.127 
The benefits of SPPS are the simplicity, easy conversion to automated 
regime, and high speed of execution compared to the synthesis in solution. 
What is more, the yield of each acylation step is up to 99.8% in case of proper 
implementation (e.g., suitable reaction time, type and amount of activator, 
number of equivalents of AAs, complete removal of the reagents by repetitive 
washing with appropriate solvents). Additionally, easy washing and purification 
procedures between the intermediate stages (by filtration) also avoid the loss of 
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material. On the other hand, to force the reaction to completion, large excess of 
reagents compared to the loading of resin is used (generally 3 to 10-fold 
excess), which increases the cost of synthesis. Next, analysis of the product at 
intermediate steps is relatively complicated.143,144 Still, there are different possi-
bilities to analyse the completion of the coupling on resin bead; e.g., colour tests 
are frequently used that show the presence or absence of certain functional 
group(s).147–149 For instance, the Kaiser test is used to analyse the presence of 
unreacted amino groups: two molecules of ninhydrin react with free amino 
group, resulting in Ruhemann´s purple colour in the presence of free primary 
amino groups (Figure 15).149 If the acylation reaction has not gone to 
completion, the coupling reaction should be repeated, or capping should be 
performed with a small and relatively cheap acylating reagent.143 
 
Figure 15. The mechanism of the Kaiser test. In the presence of free primary amino 
groups, the resin beads turn purple. 
 
2. Biochemical Assays with Detection of 
Photoluminescence 
2.1. Phenomena of Fluorescence and Phosphorescence 
Photoluminescence is emission of light from a substance after excitation of 
electron of outer molecular orbital to the higher excited state by absorption of 
photon of light. Based on the nature of excited state and intermediate states, 
photoluminescence can be divided into fluorescence and phosphorescence. The 
processes occurring during the absorption and emission of a photon of light are 
illustrated by the Jablonski diagram (Figure 16).150 Two types of transition may 
occur for relaxation of the excitated state – radiative and non-radiative. Radia-
tive transition includes the absorption or emission of a photon. One the other 
hand, non-radiative (thermal) transition involves the vibrational relaxation (i.e., 
relaxation of the excited state to its lowest vibrational level), internal conversion 
(i.e., transition from higher electronic excited state to the lower electronic  
state), and intersystem crossing (see below). In a way, the radiative transition 
 
42 
competes with non-radiative (thermal) transition, where the energy of excited 
electron is lost without the emission of photon. Thus, the fluorescence and 
phosphorescence both are more evident at low temperatures due to the 
slowdown of non-radiative decay.150,151  
 
Figure 16. The Jablonski diagram to illustrate the phenomena of fluorescence and 
phosphorescence. S0, S1 and S2 are the ground singlet state, first and second excited 
singlet states, respectively; T1 shows the first excited triplet state; vibrational energy 
levels are depicted as 0, 1 and 2. IC refers to internal conversion and is depicted as a 
dashed line; VR refers to vibrational relaxation. 
 
 
During the absorption of exciting photon, an electron of the fluorophore is 
excited to a higher excited state (S1 or S2), whereas the electron in the excited 
orbital has an opposite spin to the second electron remained in the ground state 
orbital. Thereafter, in case if the electron is excited to S1 (more common), the 
electron relaxes to the lowest vibrational level of S1 within picosecond time 
scale (10-12 s or less) during a process called vibrational relaxation, whereas the 
vibrational energy is given to the solvent; if the electron is excited to S2, first the 
electron relaxes to the lowest vibrational level of S2 (vibrational relaxation), 
followed by rapid decay to S1 due to internal conversion (Figure 16). Then, 
while the electron is returning to the ground state, a photon can be emitted and 
manifested as fluorescence, which lifetime2 is usually in 0.1-10 ns range.150  
                                                 
2
  Lifetime (τ) is an average time of the excited state of fluorophore (i.e., molecule) in 
higher vibrational levels prior to returning to the ground state.
150
 Note: the term ‘lifetime’ 















Alternatively, the excited electron can undergo a spin conversion when 
transferring from the S1 to the first triplet state T1 (intersystem crossing; the spin 
of electron in the T1 state is at the same orientation as the spin of the electron 
remaining in the ground state). As the transition from T1 to ground state is a pro-
cess ‘forbidden’ by the quantum mechanical rules, the corresponding emission, 
i.e., phosphorescence, occurs during significantly longer timescale compared to 
fluorescence, generally in μs to ms scale. Molecules that incorporate heavy 
atoms (e.g., iodine, bromine) often hold the property of phosphorescence as the 
heavy atoms enhance intersystem crossing.150 
The fluorescent substances or fluorophores are typically aromatic organic 
molecules but, on the other hand, some elements, lanthanides (e.g., europium, 
terbium) are also holding excellent properties of photoluminescence.150 The 
emission spectrum of a fluorophore depends on structure of the molecule as 
well as on the surrounding environment (pH, polarity). Generally, the energy of 
emitted photon is smaller compared to the energy of absorbed photon as there is 
an energy loss due to thermalization during decay of excited fluorophore to 
lower vibrational levels; hence, the fluorescence (as well as phosphorescence) 
appears at higher wavelength (lower energy) than excitation occured. The 
difference between the wavelength of maxima of absorption and emission 
spectra is called the Stokes shift. Furthermore, the shape of emission spectrum 
is usually not related to the excitation wavelength within absorption spectrum. 
Another important property of a fluorophore is the quantum yield characterizing 
the number of emitted photons relative to the number of absorbed photons; i.e., 
the fluorophores with high quantum yield show brighter emission.150  
The decrease of fluorescence intensity due to the enhanced non-radiative 
transition (fluorescence quenching) is caused by a variety of factors. Collisional 
quenching (or dynamic quenching) takes place when the excited fluorophore 
collides a quencher molecule in solution (e.g., oxygen, halogens, amines, 
electron deficient molecules); as a result, the quencher may either quench the 
energy or release a lower energy photon and hence the intensity of fluorescence 
(or phosphorescence) decreases.150,152 Additionally, the quenching may result 
from formation of non-fluorescent complex between the fluorophore and 
quencher before the excitation of fluorophore (so called static quenching).150   
 
 
2.2. Equilibrium Binding/Displacement Assay with  
Fluorescence Anisotropy Readout 
A phenomenon having importance in biochemical applications is fluorescence 
anisotropy (or in older literature, term ‘fluorescence polarization’ is frequently 
used). In fluorescence anisotropy-based measurements, the sample containing 
the fluorescent probe is excited by the linearly polarized light and subsequently 
polarization of emitted light is measured (for this, parallel (||) and perpendicular 
(⊥) polarizers are used). The fluorescence anisotropy (r) and polarization (P) 











                                                     (Equation 2) 
 
where I|| and I⊥ are the intensities of parallel and perpendicular polarized emis-
sion, respectively. Both fluorescence polarization as well as fluorescence aniso-
tropy can be used interchangeably as these both represent the same pheno-
menon; however, the fluorescence anisotropy is more recommended as the 
difference (I|| – I⊥) is normalized by the total intensity (IT = I|| + 2I⊥). 
The common reason for the decrease of fluorescence anisotropy is rotational 
diffusion of fluorescent probe in solution within the time in the range of fluore-
scence lifetime of the probe. As larger particles tend to rotate more slowly, the 
binding of the probe to a macromolecule leads to increase of fluorescence 
anisotropy.150 
The equilibrium binding/displacement assay with fluorescence anisotropy 
readout (FA assay) used in the current study takes advantage of change of 
fluorescence anisotropy of solution containing a fluorescent probe. Again, the 
sample is exited with linearly polarized light and, thereafter, the fluorescence 




Figure 17. The scheme of equilibrium binding/displacement assay with fluorescence 
anisotropy readout (FA assay). Protein kinase is shown in green, fluorescent probe in 
blue, and fluorescent dye in pink. 
 
 
FA assay can be performed in two formats – binding of the fluorescent probe to 
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with the protein. In binding assay, a low molecular weight (1.5…2 kDa) fluore-
scent probe (a binder possessing intrinsic fluorescence properties or a non-
fluorescent binder labelled with a fluorescent dye) binds to the active site of the 
PK (molecular weight over 30 kDa). Therefore, the rotation of PK-bound probe 
is restricted and hence the light emitted by fluorophore remains polarized 
(fluorescence anisotropy is high) (Figure 17). On the other hand, when the 
probe is free in solution (not bound to the PK), it rotates more freely, the 
emitted light is depolarized and thus the measured fluorescence anisotropy 
value is low. The data obtained from the binding format of FA assay allows the 
evaluation of equilibrium dissociation constant of the probe (KD) or the active 
concentration of the PK.  
The fluorescence anisotropy in FA-binding assay is calculated as follows 
 = (1 − ) + ∙                                     (Equation 3) 
 = ∙ /[1 + ( − 1)]                                (Equation 4) 
 = + + ∙ − [( + + ∙ ) − 4 ∙ ∙ ] /2  (Equation 5) 
 
where A correponds to the measured fluorescence anisotropy; Af and Ab are the 
values of anisotropy of free probe or the probe-enzyme complex, respectively; 
C is the total concentration of fluorescent probe, E0 is the nominal concentration 
of enzyme, k refers to the fraction of active PK (i.e., ratio of concentration of 
active PK versus nominal concentration of PK), KD is the dissociation constant 
of the fluorescent probe; Q value represents the ratio of fluorescence intensities 
of PK-bound versus free probe.111 In case if the fluorophore is not directly 
involved in binding of the compound, the value of Q is often close to 1. The Q 
value remarkably higher than 1 points to the occurrence of non-specific inter-
actions of probe with other components of the assay or binding of assay 
components to the surfaces (e.g., wall of the plastic tubes, pipette tips, wells of 
the microplate). On the other hand, the Q value below 1 may point to the 
fluorescence quenching in the probe-enzyme complex.153  
In displacement assay, the fluorescent probe is displaced from its complex 
with PK by an ATP-competitive, substrate-competitive or bisubstrate non-
fluorescent inhibitor. Consequently, the fluorescence anisotropy of emitted light 
decreases (Figure 17). The fluorescence anisotropy of displacement format of 
FA assay is calculated based on the following equations: 
 = (1 − ) + ∙                                     (Equation 6) 
 = /(3 + )                                        (Equation 7) 
 = 2( ∙ 3 ) ∙ cos −                               (Equation 8) 
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= −2 + 9 ∙ + 27 ∙ ∙ / 2( − 3 ) /    
(Equation 9) 
 = + + 10 + −                               (Equation 10) 
 = 10 − + ( − ) + ∙                     (Equation 11) 
 
where Kd corresponds to the dissociation constant of the competitive ligand and 
PK; E and L are the total concentration of active PK and total concentration of 
competitive ligand, respectively; other components are the same as previously 
described in case of binding format of FA assay. Based on the obtained data, it 
is possible to calculate equilibrium displacement constant (Kd) of the non-
fluorescent inhibitor.111  
The benefits of FA assay are its simplicity, speed, homogeneity, and readi-
ness for automation. Unfortunately, low affinity of the fluorescent probe (KD 
value higher than 10 nM) leads to the necessity to use the enzyme at high con-
centration and hence increasing price of the analysis.111 However, the developed 
probes with high affinity (KD value below 1 nM) allow the application of the 
enzyme at low nanomolar concentration.108,127,129 Also, FA assay is rarely 
applicable in biologically complex systems (e.g., live cells, cell lysates), where 
it is challenging to achieve sufficient homogeneity to excite the probe equally in 
the entire volume of the sample.150 Still, recently several examples of successful 




2.3. Determination of Association/Dissociation  
Kinetics by FA Assay 
In addition to equilibrium measurements, kinetic measurements (i.e., assess-
ment of association (kon) and dissociation rate (koff) constants) can be carried out 
with a FA assay. It is assumed that a bimolecular reaction (e.g., binding of en-
zyme and probe leading to formation of bimolecular complex) proceeds ac-
cording to the law of mass action and the rate of reaction can be expressed as 
follows: 
 +                                                  (Equation 12) 
 = − dd = − dd = dd                                        (Equation 13) 
 
where t is time, E represents the enzyme, L is a small molecular probe and EL is 
the binary complex; kon and koff are association and dissociation rate constants, 
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respectively. At equilibrium, the rate of forward and reverse reaction3 is equal 
and the equilibrium dissociation constant KD is defined as: 155,156 
 = = [ ]∙[ ][ ]                                           (Equation 14) 
 
In association experiment, the probe is added to the enzyme solution and, there-
after, the anisotropy increase corresponding to the binding of probe occurs until 
the system reaches the equilibrium (plateau phase), which position in addition 
to the affinity of the probe depends on the concentration of the probe and 
enzyme. The association is a bimolecular second-order reaction and follows the 
second order-association kinetics equation:  
 = [ ][ ]                                               (Equation 15) 
 [ ] = [ ] − [ ], [ ] = [ ] − [ ]                       (Equation 16) 
 
where k is the second-order rate constant; [E0] and [L0] are the initial con-
centrations of enzyme and probe, respectively; [E] and [L] are the concentra-
tions at time point t; [EL] is the concentration enzyme-probe complex at time 
point t. The association rate constant or on-rate constant (kon) shows the rate of 
formation of enzyme-probe complex; the unit of kon value is M-1 s-1.  
In dissociation experiment, the enzyme and probe are incubated together 
until the equilibrium is reached. Thereafter, dissociation of the probe from the 
enzyme is measured. For this, to the solution of enzyme-probe complex a large 
excess of the displacer is added that occupies the site of probe. Dissociation of 
the probe from enzyme-probe complex is a unimolecular reaction that follows 
the kinetics of the first order process, where the concentration of enzyme- probe 
complex decreases following the one-phase exponential decay equation: 
 [ ] = −  [ ]                                            (Equation 17) 
 [ ] = [ ] ∙                                       (Equation 18) 
 
where [EL] is the concentration at time point t, t is time and k is the first-order 
rate constant. The dissociation rate constant (koff) expresses the fraction of 
complex which decays per time unit; the unit of koff value is s-1 or min-1.  
A widely used characteristic of dissociation kinetics is the half-time of the 
process (t1/2), which is the period of time during which the number of complexes 
of enzyme-probe has decreased to half of its initial value. The half-life (t1/2) is 
expressed according to the following equation: 
 
                                                 
3  Rate of reaction is a measure, which shows how fast the concentration of reactants and/or 
products changes in time.155  
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/ =  ( )                                                    (Equation 19) 
 
Alternatively, a characteristic termed residence time (τ) is used, calculated as 
reciprocal of the off-rate constant: 156 
 =                                                     (Equation 20) 
 
In this work, we assumed that the dissociation of ligand from PK follows the 
classical model with the first order kinetics, which is not affected by the 
presence of competitive ligand. Recently, facilitation of dissociation of the 
complex between bifunctional ligand and PK in the presence of high con-
centrations of competive ligand (over 1 μM) had been reported.157 This is due to 
the dynamic nature of the bifunctional ligand: it is possible that at a given 
instance of time, only one fragment of inhibitor is bound to PK, whereas the 
other one is not. However, because the bound fragment holds the unbound 
fragment close to its site in PK, and hence facilitates rebinding. While a frag-
ment of the bisubstrate inhibitor stays unbound, a competitive ligand in high 
concentration can bind to the corresponding site in PK, and the formed triple 
complex causes facilitated dissociation of the bifunctional ligand. Importantly, 
the concentration of the competitive ligand must exceed a certain concentration 
to ensure its high population in proximity of PK; it was shown that less than  
1 μM competitive ligand did not facilitate the dissociation of bifunctional 
ligand.157 However, the effect may be divergent in case of different PKs, bi-
functional ligands as well as competitors.  
 
 
2.4. ARC-Lum(Fluo) Probes 
ARC-Lum(Fluo) photoluminescent probes are bisubstrate-analogue ARC-type 
inhibitors which incorporate thiophene- or selenophene-comprising hetero-
aromatic systems as ATP-analogues and are labelled with a fluorescent dye. 
The principle of operation of these tandem photoluminescent probes use both 
phosphorescence as well as a non-radiative Förster-type resonant energy trans-
fer (FRET) phenomenon (Figure 18).133  
Upon binding of ARC-Lum(Fluo) probe to PK and excitation of complex by 
flash of light in near-UV (λ < 380 nm), the FRET occurs from the excited triplet 
state of a thiophene- or selenophene-incorporating heteroaromatic system (with 
long lifetime and low quantum yield) to the singlet state of acceptor fluorophore 
(with short lifetime and high quantum yield) (Figure 18). Thereby, the energy is 
step-by-step released from the triplet state of the donor to the singlet state of the 
acceptor fluorophore via FRET mechanism. As a result, the process is leading 
to the long-lifetime luminescence emission at a wavelength corresponding to 
emission of fluorophore.133,152 However, in case of FRET phenomenon, certain 
conditions must be fulfilled. First, the absorption spectrum of acceptor must 
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partially overlap with the emission spectrum of donor [note: in the composition 
of ARC-Lum(Fluo) probes, the most efficiently are used fluorescent dyes 
absorbing light either in the orange (e.g., TAMRA, Cy3B, PromoFluor555) or 
red region of the spectrum (e.g., Alexa647), or in the intermediate zone (e.g., 
TexasRed)]. Furthermore, FRET requires the sufficient spatial proximity  
of donor and acceptor (typically the required distance is in the range of  
1–10 nm).133,150  
 
 
Figure 18. The complemented Jablonski diagram to illustrate the principle of operation 
of ARC-Lum(Fluo) probes. 1D, 1D* and 3D* denote the ground singlet state, excited 
single state and excited triplet state of donor, respectively. 1A and 1A* denote the ground 
and excited singlet state of acceptor fluorophore, respectively. IC refers to internal 
conversion and is depicted as a dashed line; VR refers to vibrational relaxation. 
 
The free ARC-Lum(Fluo) probe does not emit the long-lifetime luminescence 
in water environment, as the presence of dissolved molecular oxygen acts as a 
quencher dispelling the energy of triplet state donor into non-radiative pro-
cesses.150,152 Moreover, the long-lifetime luminescence signal of free ARC-
Lum(Fluo) probe is negligible even in deoxygenated conditions in water 
environment.152 On the other hand, when the photoluminescent probe is bound 
to the active site of PK, the probe is endowed by the long-lifetime luminescence 
emission, as the access of oxygen to the probe is hindered by PK.150,152 Hence, 
ARC-Lum(Fluo) probes are also named ‘PK binding-responsive photolumine-
scent bisubstrate probes’. Different kinases are able to ‘protect’ the photo-
luminescent probe from oxygen to a varying extent, even in case of affinity of 
ARC-Lum(Fluo) towards these PKs is similar.152  
Differently from the steady state measurement of fluorescence, measurement 
of long-lifetime luminescence intensity is performed in cycles: the sample is 
excited with a flash of light, followed by time delay to achieve decay of back-

















is carried out in a certain time window.133 ARC-Lum(Fluo) probes hold rela-
tively long-lifetime (in the two-digit s range), which provides an advantage for 
use of the probes in complicated biological systems (e.g., in cell lysate, blood 
serum, tissue extract). In this case, the measurable signal does not include the 
nanosecond range of fluorescence of organic compounds or autofluorescence of 
cells, leading to the increased sensitivity of the assay.
125,133,134
 The additional 




2.5. Assays with Time-Gated Measurement of  
Luminescence Intensity 
ARC-Lum(Fluo) probes can be used in biochemical equilibrium binding/dis-
placement assay with time-gated measurement of luminescence intensity (TGL 
assay). Similarly to FA assay, TGL assay can be performed in binding format, 
which allows determination of the concentration of active kinase or the affinity 
of photoluminescent probe, as well as in displacement format, where the affinity 
of displacing compounds (including fluorescent probes that do not possess long-
lifetime emission) can be established (Figure 19).  
 
Figure 19. The scheme of the TGL assay. PK is shown in green, photoluminescent 
probe in light blue, and fluorescent dye in dark blue. The photoluminescence signal pro-




















The benefit of the TGL assay compared to FA assay is that the negligible signal 
of free ARC-Lum(Fluo) probe enables the use of the photoluminescent probe in 
high concentrations (up to 1 mM) compared to the use of fluorescent probes in 
the FA assay (the maximal concentration of probe around 30 nM). Thus, the 
method allows the determination of affinity of compounds devoid of long-
lifetime photoluminescence (non-Lum) by shifting the IC50 value away from 
tight-binding conditions. Tight-binding conditions occur in displacement assay 
if the IC50 value of non-Lum compound stays near the half of the concentration 
of enzyme used. This understanding follows conclusions drawn according to the 
Cheng-Prusoff equation: 
 = [ ( )][ ( )]                                    (Equation 21) 
 
where Kd is equilibrium dissociation constant of the compound under evaluation 
and IC50 corresponds to the concentration of non-Lum compound at which the 
amount of complex of probe and kinase is half of maximum; c[ARC-Lum(Fluo)] 
and KD[ARC-Lum(Fluo)] correspond to the concentration and equilibrium 
dissociation constant of photoluminescent probe used, respectively.129,133 Next, 
differently from the frequently used surface plasmon resonance (SPR) method, 
ARC-Lum(Fluo)-based assays are homogenous, automatable and well suitable 
for the high throughput screening of small-molecule ligands. Furthermore, 
ARC-Lum(Fluo) probes can be utilized not only in thermodynamic measure-
ments, but also in kinetic measurements – where under suitable conditions, 
association and dissociation rate constants of the displacing compounds can be 
established (discussed in Results and Discussion).133  
 
 
2.6. Thermal Shift Assay 
Thermal shift assay (also known as differential scanning fluorimetry, DSF) is a 
fast and relatively inexpensive method for the characterization of stability of 
native protein versus low molecular weight ligand-bound protein.158,159 Thermal 
shift assay measures the thermal unfolding (denaturation) of the protein in the 
presence of a fluorescent dye and this method is used for screening of ligands 
against the protein(s) under investigation.127,160–164      
The stability of protein is related to its Gibbs free energy of unfolding, ΔGu. 
Along with the increase of temperature, the stability of protein decreases.158 
During this process, hydrophobic regions of the protein are revealed, where a 
suitable fluorescent dye can bind (Figure 20). The fluorescent dye must be 
highly fluorescent in non-polar environment (e.g., when bound to the hydro-
phobic regions of unfolded protein) and, on the other hand, in aqueous environ-
ment the fluorescence of free dye must be strongly quenched.158 One of the 
most used dyes is SYPRO orange due to its high signal-to-noise ratio and high 
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excitation wavelength (near 500 nm), which decreases the risk of excitation of 
other molecules in solution.158,160,163 
Consequently, the fluorescence quantum yield and hence fluorescence inten-
sity of the dye increases with rising temperature, reaching its maximum at the 
temperature where the protein is in a completely unfolded state. After the maxi-
mum signal is achieved, the fluorescence intensity starts to decline due to the 
aggregation or precipitation of protein at even higher temperatures. The tempe-
rature at which the amount of native and unfolded protein is equal or the fluore-
scence intensity of the protein-dye complex is half of the maximum, is called 




Figure 20. The melting curves of a protein obtained by thermal shift assay. The blue 
curve corresponds to a native protein and the green curve to a ligand-bound protein. The 
native and the unfolded protein is marked as a circle and an irregular shape, respec-
tively; the protein-bound ligand is marked as a red rhombus and the molecules of 
fluorescent dye SYPRO orange shown as orange ovals. The difference between the 
melting temperature of ligand-bound versus native protein (ΔTm) is highlighted in red. 
 
 
In most cases, the binding of ligand can increase the stability of the protein due 
to the contribution of the Gibbs free energy of ligand binding (ΔGl) to the 
ΔGu.
158,160 Reflecting the increase of ΔGu of protein, the binding of the ligand to 
protein generally leads to the positive shift of Tm compared to the native protein. 
The difference between the melting temperature of ligand-bound versus native 
protein is called the thermal shift value, ΔTm.
158 The studies have shown that the 
ΔTm values obtained by thermal shift assay are proportional to the affinity of 
ligand determined with other methods (e.g., equilibrium binding/displacement 




implies that ΔTm values around 4 °C usually correspond to Kd values of below 1 
μM, whereas ΔTm values over 8 °C generally correspond to the Kd values below 
100 nM.161–163  
Fluorescence intensity measured by thermal shift assay can be plotted as a 
function of temperature resulting in sigmoidal curve (Figure 20). The inflection 
point of transition, i.e., Tm value, is calculated by using Boltzmann equation: 
 ( ) = + ( )(  ( )                               (Equation 22) 
 
where the Max and Min are the values of maximum and minimum fluorescence 
intensities, respectively, T is the temperature, y is the measured fluorescence 
intensity, and a corresponds to the slope of the curve within Tm.158,160  
The advantages of thermal shift assay include the possibility to use the 
native protein and non-labelled ligands, which eliminates the risk that the label 
of protein and/or ligand may influence the behaviour of the parties in assay. 
Other benefits include relatively quick implementation as many samples can be 
analysed simultaneously, easy set-up of the experiment, and relative cheapness 
of the assay.158 On the other hand, the ΔTm values may sometimes not reflect the 
relative affinities of ligands towards certain protein targets, hence it is some-
what risky to rank the binding affinities of ligands only according to ΔTm 
values.160,165  
 
3. Protein Crystallography 
3.1. Principles of Protein Crystallography 
Crystallography is a technique in where a single crystal is irradiated by focused 
X-ray beam and a two-dimensional diffraction pattern is recorded. X-ray radia-
tion has a wavelength of 0.1 to 1000 Å (or 10-11 to 10-7 nm), but in crystallo-
graphy, 0.4 to 25 Å X-ray radiation is used as it corresponds to the length of 
chemical bond.166 Thereafter, the re-calculation of diffraction data by using 
Fourier method provides the three-dimensional electron density map re-
presenting the crystal lattice components. Finally, into the electron density map 
the atomic model of the structure is built in.166 
X-ray crystallography allows the determination of highly detailed and 
precise spatial arrangement of atoms of macromolecules (such as proteins) in 
the crystal. As the 3D-structure of the molecule usually reflects its function 
or/and mechanism of action, crystal structures have been used to study PPIs, 
establish the enzymatic mechanisms of proteins, and provide  essential insight 
for the structure-guided drug design.166 More than 127,000 structures of pro-
teins, including co-crystal structures of proteins with small-molecular ligands or 
co-factors, were deposited in Protein Data Bank (PDB) for January 17th 2018. 




A crystal is a three-dimensional substance, where the molecules are regularly 
arranged into crystal lattice.170 Protein crystals are different from inorganic 
crystals in several aspects. To start with, the protein crystals contain a large 
amount of solvent (water content 40–60% of crystal volume), allowing relati-
vely free diffusion of small compounds through the crystal. Moreover, high 
water content helps to maintain the native conformation of the protein in crystal. 
Evaporation of liquid leads to the destabilization of the crystal and, as a result, 
the loss of crystalline order and diffractive properties; therefore, the crystals 
must be maintained inside the ‘mother liquor’ and at a sufficiently low tempera-
ture. Another essential difference from inorganic crystals is that in protein 
crystals, the atoms are not located at the nodes of unit cell. Furthermore, the 
biomacromolecules are extremely sensitive to the change of environmental 
conditions (pH, temperature, radiation damage, etc; radiation damage discussed 
more precisely below in section of Preparation for Diffraction Data Measure-
ment).170 
The acquisition of crystal structure of a protein involves four main steps 
discussed below. Note: only these processes are discussed in detail in which the 
author has been directly involved and the description is focused on water-
soluble proteins with globular structure.   
 
1. Crystallization 
Crystallization is a process where a protein gradually precipitates out from the 
solution and forms a regular crystal lattice.170 The structure of protein must 
favour the self-assembly of molecules into periodic crystal lattice by facilitating 
intermolecular interactions.166 All molecules of the protein should have the 
same surface properties, especially the charge distribution to contribute the 
interactions between the molecules during packing into crystal structure.170 
Thus, a crucial requirement for the protein sample is purity: the higher is the 
purity (required ≥ 95%) as well as freshness of protein (i.e., reduce the 
oxidation damage, denaturation), the greater is the chance for formation of 
crystal.170,171  
Next, to induce the precipitation of protein and facilitate the formation of 
protein crystals, an appropriate solvent must be used (usually water-buffer 
system where an organic solvent is added). On the other hand, the protein of 
interest must be soluble in this solvent, and the environment should be as 
similar to the physiological as possible. Furthermore, the salts (e.g., ammonium 
sulphate), organic compounds (e.g., 2-methyl-2,4-pentanediol, MPD) or 
polyethylene glycol (PEG) can be added to induce precipitation of protein.170 
Proteins are polyvalent ions, hence its surrounding by other ions influences the 
interactions of proteins with water molecules and thus the solubility. Most 
proteins are soluble in water environment in the presence of a low concentration 
of salts (so-called ‘salting in’). Still, simultaneously with the increase of con-
centration of salt, the solubility of protein decreases (so-called ‘salting out’) as 
water molecules are taken away from the surrounding of protein into the 
hydration layer around the ions of salt. Frequently, ammonium sulphate is 
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applied due to its high solubility and non-harmfulness for protein at high con-
centrations. The addition of PEG functions similarly.170,171 Also, the effect of 
organic solvents is to clench the ionic layer on the surface of protein and thus 
allow the protein molecules to approach each other and aggregate, when a 
suitable orientation is achieved. On the other hand, the organic solvents might 
denature the proteins and hence the concentrations must be kept at moderate 
level and the experiments performed at low temperature.171 What is more, 
crystallization is also promoted by modification of pH and temperature or 
addition of protein-stabilizing cofactors, metal ions, etc.170,171 Finally, an 
important factor is also time, as the equilibrium formation between the soluble 
and crystallized form of protein is time-consuming.170  
The process of crystal growth has been well characterized for small molecule 
crystals, the process has been considered to be similar for proteins. First, the 
formation of supersaturated solution is required where small protein aggregates 
can spontaneously form the nucleation centres (or nuclei) required for crystal 
growth (Figure 21). Thereafter, the supersaturation of solution must be kept at 
lower level (e.g., by changing the temperature or concentration of precipitation 
agent) to prevent formation of numerous nuclei and thus avoiding the growth of 
numerous low-grade minute crystals. Instead, the growth of few crystals with 
sufficient size is favored. Moreover, the slower growth of crystals increases the 




Figure 21. Pictures of growth of Haspin/ARC-1411 (top row) and Haspin/ARC-668 
(bottom row) co-crystals in time under 3.3x magnification. The crystallization method 
used was the sitting drop method.  
 
A frequently used crystallization technique method is vapor diffusion, pos-
sessing popularity due to the opportunity to use small amount of protein and 
simple realization. The current technique can be divided into 1) hanging drop 
and 2) sitting drop methods. In hanging drop vapor diffusion method, the 
protein and precipitant solutions are mixed on a siliconized glass cover slip and 
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placed upside down over reservoir which is partially filled with a suitable 
precipitant. On the other hand, in sitting drop method, the drop of the protein 
solution locates in microwell adjacent to the reservoir with precipitating 
solution and the reservoir as well as microwell are covered with a seal. In both 
methods, the water evaporates from the droplet and condenses to the reservoir 
solution, causing the increase of concentration of precipitating agent in the 
protein droplet. Evaporation of water from the drop is caused by the con-
centration difference of precipitating agent in droplet and reservoir and it occurs 
until the concentrations are equal, i.e., equilibrium is reached. The vapour 
equilibrium between the protein droplet and precipitating agent solution in 
reservoir allows the protein solution to reach supersaturation and then formation 
of crystallization centres. Additional benefit of vapor diffusion method is the 
possibility to manipulate with time of arrival of equilibrium by varying the 
distance between the droplet and reservoir. Furthermore, the concentration of 
solution in reservoir and the concentration of protein in the microwell can easily 
be modified by diluting.170     
Despite the fact that the theoretical background of crystallization of proteins 
is well known, the parameters necessary for crystal formation within a 
reasonable period vary significantly. In order to find optimal conditions, large 
number of variables (concentration of protein, nature and concentration of 
precipitant, pH, temperature, and/or specific additives in low concentrations) 
are screened simultaneously. After the initial crystals are obtained, the fine 
screens are performed near the suitable condition to obtain the crystals with 
good quality and sufficient size.171  
 
2. Preparation for Diffraction Data Measurement 
After the protein crystals with sufficient size are formed, the following step is 
the removal of a suitable crystal from the growth medium (crystal mounting). 
The mounted crystal is usually kept hydrated in mother liquor to avoid the 
evaporation of water. Generally, the loop made of fine fibers (nylon loop or 
cryo-loop) is used, which does not counteract the data collection at different 
positions of the sample and thus avoids the need for additional manipulation 
with the crystal before the X-ray experiment. A thin liquid layer spanning the 
loop keeps the crystal inside the loop due to the surface tension of the 
liquid.170,171 
As previously mentioned, the biomolecules are extremely sensitive to 
radiation damage. The radiation damage of biomolecules is caused by exposure 
of crystal to high energy X-rays; photons with high energy cause the formation 
of free radicals (e.g., monooxygen or hydroxyl radicals) inside the macro-
molecule or solvent, which upon diffusion through the crystal cause the 
destruction of crystalline order. In order to reduce the effect of radiation 
damage, sensitive X-ray detectors are used to reduce the exposure time. The 
radiation damage can also be remarkably reduced by cooling the crystals to 
cryogenic temperatures (100-120 K) before the measurement of diffraction 
pattern; at low temperatures, the radicals can still be formed but their diffusion 
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through the crystal is eliminated. The data collection at cryogenic temperatures 
(cryocrystallography) allows the prolonged exposure time as well as collection 
of many datasets from the crystal at different wavelengths.166,170  
The cryogenic cooling must be performed rapidly (so-called flash-freezing 
or shock cooling) to facilitate the freezing of water in a vitreous state and 
prevent the formation of crystalline ice, which may cause formation of cracks in 
the crystal and hence decrease the quality of diffraction pattern. Cryogenic 
cooling can be performed by placing the crystals into the stream of cold nitro-
gen gas or immersing those into liquid nitrogen. Moreover, with the aim to 
reduce the damage of crystal during flash-cooling, cryoprotectans (e.g., 
glycerol, PEGs of different molecular weight, MPD) are applied before the 
shock cooling; alternatively, the crystal can be grown in the medium already 
containing cryoprotective agent (e.g., methanol).170,171 Still, flash-cooling of 
crystals of some protein may be difficult under certain circumstances, and it is 
impossible to avoid the damage of certain functional groups during the exposure 
to X-rays (e.g., cleavage of disulphide bond).170 
 
3. Data Collection 
During the exposure of protein crystal to X-rays, the phenomenon called X-ray 
diffraction occurs. Diffraction takes place when the wave encounters an 
obstacle (e.g., atom) on its way; if the dimensions of an obstacle are in the range 
of light wavelength, bending of the wave around the obstacle occurs (Figure 
22). There, the obstacle functions as a new source of the waves, generating new 
waves with different spreading directions compared to the initial wave. The 
resulting waves are able to interfere (i.e., the waves combine and give a new 
wave) by getting stronger or cancelling each other out (constructive and 
destructive interference, respectively), hence generating a diffraction pattern of 





Figure 22. Diffraction from a crystal. d corresponds to the distance between the atoms 
(shown as orange spheres) in the crystal.  
Beam of X-rays
Direction of light propagation
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The pattern of reflections can be recorded with an area detector, a single-photon 
counter, or a photographic film.170 The intensity and position of spots of 
diffraction pattern provide information about the locations of atoms and the 
repetitive distance d in the crystal, respectively.166,170 The direction of diffracted 
beam depends on the X-ray wavelength as well as the unit cell distances in the 
crystal.170  
The diffraction of a protein crystal is relatively weak as compared to the 
crystal of metals or small molecules containing heavy atoms, because proteins 
mostly consist of atoms with a small number of electrons (i.e., C, N, O). Be-
sides, the diffraction is a cooperative effect of the atoms positioned identically 
in an elementary cell; as the molecular weight of protein molecule is high, the 
number of particles in crystal is relatively low which additionally contributes to 
the weak diffraction intensities. Therefore, in order to obtain the diffraction 
pattern with reliable quality, it is essential to use high intensity source of X-rays 
(e.g., synchrotron).170  
 
4. Data processing and analysis 
The diffraction pattern provides a two-dimensional picture from which it is 
possible to reconstruct three-dimensional crystal lattice using Fourier transform 
techniques. However, in order to generate the electron density map, both the 
amplitude as well as relative angle of phase of each reflection must be known. 
While the amplitude can be measured directly, as it is proportional to the square 
root of measured reflection intensities, the detectors do not record the phase of 
wave. This limitation is known as a phase problem. Different methods can be 
used to solve the phase problem (e.g., molecular replacement), and when the 
initial phase is found, it is possible to construct the initial atomic model: the 
atoms of protein are placed into the obtained electron-density map.166,170  
The final step during the data processing of diffraction data is refinement. 
The set of structure factors is computed for the present atomic model and com-
pared to the experimentally obtained data; next, the parameters of the model are 
modified until there is no remarkable improvement in correlation between the 
atomic model and the experimental data. The agreement between the calculated 
and experimental model is expressed as the R-value, which is defined as the 
reliability or residual index. Thus, in case of perfect compliance, i.e., no 
difference between the calculated and observed values, R is equal to zero; along 
with the increase of differences, the R-values increases as well; normally, R-
value remains below 20%.166,170 As protein crystals are not rigid structures, 
difficulties may arise during definition of the electron density for highly flexible 
and mobile fragments of proteins. Often, the electron density map is absent or 
poorly defined for N- or C-termini of the protein chain as well as for flexible 
loops connecting secondary structure elements.166 
The quality of diffraction pattern is related to the quality of crystal, i.e., 
regularity of the molecules in crystal lattice, and hence can be interrupted by 
crystal defects.170 The reliability and quality of the collected data is charac-
terized by the observed resolution corresponding to lattice spacing.170,171 
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Resolution is defined as the minimal identifiable distance between the structural 
elements in electron density map.170 If the resolution remains in same magni-
tude as the length of chemical bond, then such a bond can be modeled with a 
high precision. In case of crystal that diffracts to resolution over 4.5 Å, it is 
possible to obtain only rough information about the shape of protein; the 
minimal required diffraction remains at the range of 3.5 Å. The resolution of 
good quality and high quality data is 2.0-2.7 Å (note: 2.7 Å is a minimal 
resolution to well-define water molecules) and 1.0-2.0 Å (1.5 Å is length of 
typical C-C covalent bond; 1.2 Å is a full atomic resolution), respectively.170–172 
However, the quality of crystal structure of protein also strongly depends on 
other structural factors and the claimed resolution may only be apparent.172 
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RESULTS AND DISCUSSION 
In the subsequent scheme, the step-by-step workflow used for development of 
novel Haspin-targeting compounds is presented. The general structure of this 






1. Screening of the Inital Set of  
ARC-Scaffold Towards Haspin   
[Paper I: Kestav et al., 2015] 
The first step in developing Haspin-targeting inhibitors and fluorescent probes 
involved the screening of ARC-based fluorescent probes towards mitotic kinase 
Haspin. For this, the equilibrium binding assay with fluorescence anisotropy 
(FA) readout was used. The aim of this was to choose the suitable high affinity 
fluorescent probe(s) for the further screening of non-fluorescent ARCs. The 
probes represented structurally diverse scaffolds; however, all of those incor-
porated the fluorescent dye with similar optical properties (i.e., TAMRA or 
Cy3B) as well as an oligoarginine fragment, as it was presumed that Haspin as a 
basophilic PK42 should possess high affinity towards compounds comprising the 
positively charged Arg residues. The probes had previously shown low nano-
molar or subnanomolar dissociation constants (KD values) in studies with diffe-
rent basophilic PKs (e.g., PKA, cGMP-dependent PK, Rho-kinase ROCK2) and 
a relatively wide selectivity profile in commercial PK panels.111,126,129,133,173 The 
codes and schematic structures of ARC-based probes are given in Table 4. 
 
 
Table 4. Schematic structures, values of equilibrium dissociation constant KD of fluore-
scent probes as established in the equlibrium binding assay with Haspin 
Compound Schematic Structure KD, nM** 
ARC-583 Adc-Ahx-DArg6-DLys*(TAMRA)-NH2 2.0 (0.8) 
ARC-669 AMTH-Ahx-DArg-Ahx-DArg6-DLys*(TAMRA)-NH2 9.2 (2.5) 
ARC-1042 Adc-Ahx-DArg-Ahx-DArg6-DLys*(TAMRA)-NH2 0.91 (0.28) 
ARC-1059 H9-(CH2)5-C(=O)-DArg6-DLys*(TAMRA)-NH2 2.0 (0.3) 
ARC-1081 Adc-Ahx-DArg-Ahx-DArg6-DLys*(Cy3B)-NH2 1.0 (0.2) 
ARC-1144 AMSE-Ahx-DArg-Ahx-DArg6-DLys*(TAMRA)-NH2 23 (8) 
* reveals the attachment of fluorescent dye to the side-chain of DLys; ** standard error 
values are given in brackets (N ≥ 2). 
 
The assay showed that ARC-1042 and ARC-1081 possessed the highest affi-
nity towards Haspin (KD values of 0.91 nM and 1.0 nM, respectively). Both 
probes were derived from the same non-labelled precursor compound com-
prising adenosine-4'-dehydroxymethyl-4'-carboxylic acid moiety (Adc) as the 
ATP-site targeting fragment, two 6-aminohexanoic linkers (Ahx) separated by 
DArg residue as the chiral spacer, and the (DArg)6 peptide as the peptidic frag-
ment with amidated C-terminus.  
Having sieved out the suitable probes with high affinity, the subsequent step 
involved the screening of non-fluorescent ARCs towards Haspin by applying 
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the equilibrium displacement assay with FA readout; ARC-1081 was used as 
the fluorescent probe. The screening set included variable structural scaffolds 
with the aim to identify the conjugates that could serve as lead compounds for 
development of Haspin-targeting inhibitors (Table 5). All the compounds of 
screening set were previously reported ARCs or their analogues121,122,126,173,174, 
whereas the structural differences were as follows:  
 different ATP-site-targeting fragments,  
 different chirality and number of arginine residues (0, 2, 6 or 8) in the 
peptidic fragment,  
 different structure and number of linkers (1 or 2),  
 incorporation of a chiral spacer between the linker moieties,  
 and attachment of a fatty acid moiety.  
Schematic structures of compounds of the screening set together with the 
obtained Kd values are shown in Table 5 (note: here and in the following discus-
sion Kd indicates the equlibrium dissociation constant of non-fluorescent con-
jugates). 
Not suprisingly, the data revealed that the affinity of conjugates towards 
Haspin was strongly dependent on the number of Arg residues in peptidic frag-
ment, the same tendency had also been reported previously in studies with other 
basophilic PKs.121,126,131 Generally, the addition of two Arg residues gave two 
orders of magnitude gain in affinity (e.g., series: ARC-1034 → ARC-582 → 
ARC-902). However, the affinity increase was only observed up to 6 Arg 
residues in the peptidic part, as 8 residues did not cause significant improve-
ment of affinities (ARC-902 versus ARC-1090 or ARC-1197). Next, DArg 
residues in peptidic fragment of conjugates were preferred over L-isomers 
(ARC-902 versus ARC-341). The chirality of spacer between the flexible Ahx 
linkers had no observable effect on the affinity of conjugates for Haspin (ARC-
1012 versus ARC-1038). The latter effect differed from the previous studies 
with PKA C, where the D-amino acid as chiral spacer was essential for the high 
affinity of conjugates.126 The attachment of fatty acid moiety, i.e., myristoyl 
moiety (Myr), generally led to drop in affinity of conjugates (ARC-684 versus 
ARC-685 or ARC-1141 versus ARC-1143). The latter observation could 
probably be attributed to the fact that the positive charge of the side-chain of 









Table 5. Schematic structures and values of the dissociation constant Kd of non-
fluorescent conjugates of initial set established in the displacement assay with Haspin 
and fluorescent probe ARC-1081 
Compound Schematic Structure Kd, nM** 
ARC-1010 Adc-Ahx over 15000 
ARC-1034 Adc-Ahx-DArg2-NH2 3400 (400) 
ARC-582 Adc-Ahx-DArg4-NH2 110 (8) 
ARC-902 Adc-Ahx-DArg6-NH2 2.6 (0.3) 
ARC-1090 Adc-Ahx-DArg8-NH2 9.0 (1.1) 
ARC-341 Adc-Ahx-LArg6-NH2 40 (4) 
ARC-342 Adc-Ahx-LArg6-LLys-NH2 33 (2) 
ARC-1012 Adc-Ahx-DLys-Ahx-DArg2-NH2 2000 (200) 
ARC-1038 Adc-Ahx-LLys-Ahx-DArg2-NH2 2000 (100) 
ARC-1041 Adc-Ahx-DArg-Ahx-DArg6-DLys-NH2 0.24 (0.11) 
ARC-1176 AMTH-Ahx-DArg-NH2 over 15000 
ARC-1102 AMTH-Ahx-DLys-Ahx-DArg2-NH2 over 15000 
ARC-668 AMTH-Ahx-DArg-Ahx-DArg6-DLys-NH2 15 (3) 
ARC-1141 AMTH-Ahx-DAla-DArg6-DLys-Gly 16 (3) 
ARC-1143 AMTH-Ahx-DAla-DArg6-DLys*(Myr)-Gly 66 (5) 
ARC-1197 AMTH-Ahx-DArg-Ahx-DArg6-DLys*(-C(=O)-(CH2)7-C(=O)-DArg6-NH2)-NH2 
4.7 (0.5) 
ARC-3009 H9-C(=O)-CH2-NH-CH2-C(=O)-DArg2-NH2 over 15000 
ARC-3010 H9-C(=O)-CH2-NH-CH2-C(=O)-DArg6-NH2 800 (160) 
ARC-903 H9-(CH2)5-C(=O)-DArg6-NH2 37 (3) 
ARC-1408 PIPY-C(=O)-(CH2)7-C(=O)-DArg-Ahx-DArg-NH2 3700 (600) 
ARC-1411 PIPY-C(=O)-(CH2)7-C(=O)-DArg6-DLys-NH2 11 (2) 
ARC-684 PYB-Ahx-DArg-Ahx-DArg6-DLys-NH2 17 (3) 
ARC-685 PYB-Ahx-DArg-Ahx-DArg6-DLys*(Myr)-NH2 390 (50) 
ARC-3125 TIBI-CH2-C(=O)-Ahx-DArg6-DLys-NH2 0.56 (0.09) 
- DArg9-NH2 over 15000 
The compounds are listed in alphabetical order according to their ATP-site binding 
fragments. * reveals the attachment of the fragment indicated in brackets to the side-






Next, Adc as the nucleosidic fragment possessing similarity to ATP and com-
prising several chirality centres was preferred over the planar and non-chiral 
aromatic systems such as AMTH or H9 (ARC-902 versus ARC-668 or ARC-
903). The comparison of compounds ARC-1041 and ARC-902 both com-
prising Adc and Arg6 fragment, revealed that the elongation of linker together 
with the introduction of chiral spacer increased the affinity. Similar trend had 
been reported for PKA C.126 On the other hand, the conjugates incorporating 5-
(2-aminopyrimidin-4-yl)-thiophene-2-carboxylic acid moiety (AMTH) did not 
show the latter effect in case of similar structural modification (ARC-668 
versus ARC-1141). Moreover, the importance of flexibility and length of linker 
of conjugates was demonstrated in a series incorporating Hidaka´s inhibitor H9. 
In particular, ARC-3010 comprising a relatively short rigid linker possessed 
over 20-fold lower affinity than its counterpart ARC-903 incorporating a more 
flexible linker. 
Finally, in addition to ARCs, the affinity of the compound comprising Adc 
moiety and a linker (ARC-1010) and that of nona-arginine peptide alone 
(DArg9-NH2) was established. As expected, the results revealed that at the 
highest used concentration, none of the fragments were able to completely 
displace the fluorescent probe from the compex with Haspin. Thus, the impor-
tance of conjugation of fragments to achieve higher affinity towards Haspin was 
demonstrated.   
Overall, the results indicated that the positively charged Arg residues in 
peptidic fragment facilitate the binding of conjugates to Haspin. Furthermore, the 
importance of ATP-site fragment together with the linker structure (flexibility 
versus rigidity) for binding of conjugate was demonstrated, however, the effect 
was not as significant as number of Arg residues in the peptidic fragment.  
 
The Initial Selectivity Profile Determination of ARC-Based Conjugates 
of the Initial Set of Compounds 
With the aim to determine the selectivity profile of the initial set of ARCs, the 
thermal shift studies were performed with Haspin as well as CMGC kinase 
family members Clks (Cdc2-like kinases) and DYRK2 (dual-specificity tyro-
sine (Y)-phosphorylation regulated kinase 2). These PKs were chosen based on 
the reported off-targets of Haspin-selective inhibitor 5-ITu.90 
The results revealed that the data established in displacement assay and in 
thermal shift assay with Haspin were in good correlation, i.e., the higher ΔTm 
values corresponded to lower IC50 (or Kd) values, hence reflecting the higher 
affinity of compounds (Table 6). As discussed above, ΔTm values around 4 °C 
usually correspond to Kd values below 1 μM, whereas ΔTm values over 8 °C 
generally correspond to Kd values below 100 nM.161–163 Interestingly, ARC-685 
and ARC-3010 represented the outliers from the general trend, as those con-
jugates possessed lower ΔTm values than expected based on their affinity. 
Overall, 7 compounds out of 15 showed ΔTm values over 5 oC, thus indicating 
submicromolar range of potency. Importantly, all these conjugates incorporated 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The ΔTm values of conjugates in complexes with Clk1, Clk2, Clk3 and DYRK2 
were considerably lower than in the corresponding complexes with Haspin. The 
results indicated that Haspin possessed the higher affinity for conjugates that 
comprised the oligoarginine fragment, whereas other tested PKs showed the 
preference based on the nucleosidic fragment, whereas generally AMTH, PIPY 
and TIBI moieties were preferred. This was not surprising as neither DYRK nor 
Clk family are considered classically basophilic, although the consensus se-
quences of their substrates do contain Arg in the certain positions relative to the 
phosphorylatable residue.175,176 
Overall, based on the results established in the screening of ARC-based con-
jugates of initial set, two lead compounds ARC-1141 and ARC-902 were 
chosen for the co-crystallization with Haspin. Both of those conjugates con-
tained oligoarginine fragment in their peptidic part, but incorporated different 




2. Rational Design and Biochemical Characterization of 
Haspin-Targeting Bisubstrate-Analogue Inhibitors 
[Paper I: Kestav et al., 2015; unpublished data] 
Co-Crystal Structures of Haspin with ARC-Based Lead Compounds 
The crystallization studies resulted in co-crystal structures with high resolution 
(resolution of 1.87 and 1.70 Å for ARC-1141 and ARC-902, respectively) and 
both structures showed typical space group P212121 for the kinase domain of 
Haspin (Table 7). Expectedly, ARCs were bound to the catalytic cleft of 
Haspin, whereas the nucleosidic fragment was buried deeper into the cleft 
between the N- and C-lobe; at the same time, the peptidic fragment was more 
directed into the solvent (Figure 23 and Figure 24). Also, the electron densities 
corresponded to the nucleosidic fragment and linker part were unambigously 
defined. On the other hand, despite the observed high resolution of crystal 
structures of ARC-1141 and ARC-902, the electron densities of peptidic part 
were only defined for two (in case of ARC-1141) or three (in case of ARC-
902) arginine residues and, therefore, it was suggested that oligoarginine frag-
ments are relatively mobile and could adopt multiple conformations (Figure 23 
and Figure 24). Despite the high resolution, the overall quality of structural 
factors was low and hence the crystal structures were not deposited into Protein 









Table 7. Structural factors of co-crystal structures of ARC-1141 and ARC-902 with 
Haspin 
Characteristics ARC-1141:Haspin ARC-902:Haspin 
Resolution (Å) 1.87 1.70 
R-value 0.160 0.153 
Space group P212121 P212121 
 
 
In co-crystal structure of ARC-1141 with Haspin (Figure 23), the exocyclic 
nitrogen of AMTH moiety functioned as a donor of H-bond for Glu606 of 
Haspin (the same interaction between the N1 amino group of AMP and Haspin, 
see Figure 7). Also, the hydrophobic stacking occured between the aromatic 
AMTH moiety and Phe607. Interestingly, the hydrophobic linker following 
AMTH moiety made a sharp turn (ca 90⁰), whereas such positioning had not 
been seen previously in co-crystals structures of ARCs with PKs.126,177 The 
backbone nitrogen of the first DArg following the linker (DArg#1) formed H-
bond with Gln718, wherein no interaction was seen for the side-chain of the 
same arginine residue. Still, the guanidinium group of DArg#1 of ARC-1141 
was probably involved in π-π stacking with the amide bond between Gly715 
and Asp716 of Haspin. Next, DArg#2 protruded up to the G-rich loop and 
formed two charge-reinforced H-bonds with the backbone carbonyl of Glu492. 
Figure 23. Co-crystal structure of ARC-1141 with Haspin kinase domain. PK is 
indicated as green cartoon and ARC as coloured sticks; G-rich loop is shown as black 
cartoon; residues of PK that form the interactions with the co-crystallized compound are 





Differently from ARC-1141, ARC-902 gave remarkably higher number of H-
bonds with the kinase domain of Haspin. Similarly, ATP-site targeting Adc 
moiety formed analogous interactions with Haspin as AMP and ARC-1141 
(Figure 7 and Figure 23, respectively) i.e., a H-bond with Glu606 and a hydro-
phobic interaction with Phe607 of Haspin. However, the polar interaction with 
Gly608 was missing. The hydroxyls of ribose moiety of ARC-902 developed 




Figure 24. A) Co-crystal structure of ARC-902 with Haspin kinase domain. PK is 
indicated as cyan cartoon and ARC as coloured sticks; G-rich loop is shown as black 
cartoon; residues of PK that form the interactions with the co-crystallized compound are 
shown as lines and are labelled; hydrogen bonds are shown as black dotted lines. B) 
Overlay of co-crystal structures of ARC-1141 (green) and ARC-902 (cyan). PK is 
indicated as cartoon. The G-rich loop as well as the loop following the upper lobe helix 
(α-uIH) are showed by black and red arrows, respectively. 
 
 
The linker fragment Ahx was positioned under the G-rich loop, which had been 
previously seen from co-crystal structures of ARCs with PKA C (Figure 
24).126,177 Also, the carbonyl of Ahx gave H-bond with the backbone nitrogen of 
Phe495. As a result, the co-crystal structure of ARC-902 with Haspin showed 
more closed conformation compared to the complex of Haspin with ARC-1141 
(Figure 24, B). Next, DArg#1 of ARC-902 formed polar contacts with the C-
lobe residues Asp649 and Thr689, whereas the latter interactions reflected the 
typical binding pattern of ARCs revealed within the previous studies with PKA 
C.126,177 The next arginine residue (DArg#2) flipped over the G-rich loop and 
gave H-bonds with the residues of N-lobe of Haspin, i.e., Ala587 and Asn588. 
The latter interactions were similar to the binding pattern of H3(1-7): Arg2 of 
H3 was protruded to the pocket between the G-rich loop as well as the loop 
  
69 
following α-ulH of Haspin and developed H-bond with Asn588 (Figure 32, 
Figure 24).54 The last arginine for which the electron density was still defined 
(DArg#3) was positioned to Haspin in two different conformations, whereas the 
interactions were developed with Glu613 and Gln718 or Gly653 and Asn654. 
In case of the latter conformation, a π-π stacking also occurred between the 
guanidinium group of DArg#3 and the imidazole ring of His651 of Haspin. 
 
Principles of Design of New Set of ARC-Inhibitors 
The subsequent step in rational design of Haspin-tageting conjugates involved 
the comparison of co-crystal structures of Haspin with ARCs (i.e., ARC-1141 
or ARC-902) or H3(1-7) (PDB 4OUC), which was published by Maiolica and 
co-workers in 2014.54     
The ATP-site targeting fragment was chosen based on the results of 
structure-affinity studies. Thus, AMTH and Adc moiety were chosen as the 
ATP-site targeting fragments of conjugates. The previous studies have revealed 
that the oligoarginine fragment contributes to the increase of affinity, but often 
leads to the loss of selectivity towards basophilic PKs. Previously, Uri and co-
workers had demonstrated that substitution of oligoarginine peptidic fragment 
of conjugates with oligoaspartate or oligoaspartate-imitating peptoid fragment 
resulted in high affinity as well as selectivity of conjugates for acidophilic PK 
CK2.108,130,132 Therefore, with the aim to incease the selectivity of compounds 
towards Haspin, H3(1-7)-like peptide representing an analogue of the substrate 
of Haspin was used as the Haspin substrate-site targeting moiety of new con-
jugates.  
Next, it was necessary to identify the suitable positions for linking ATP-site 
fragment and H3-like peptide. The overlay of co-crystal structure of Haspin 
with ARC-based lead compounds ARC-1141 or ARC-902 with 5-ITu and 
H3(1-7) (PDB 4OUC) revealed two positions in the structure of H3(1-7), which 
were used to link the fragments (Figure 25). In particular, the linking in the 
proximity of the N-terminus of peptide led to the generation of Set A 
compounds, and the linking in the proximity of the phosphorylatable Thr3 led to 






Figure 25. A) Overlay of co-crystals of ARC-1141 (green) versus histone H3 (magenta; 
residues 1-7, PDB 4OUC) with Haspin. B) Overlay of co-crystals of ARC-902 (blue) 
versus histone H3 (magenta; residues 1-7, PDB 4OUC) with Haspin. PK is indicated as 
cartoon; ARCs as sticks and H3 as lines; the black circles show the locations where the 
linkage between the nucleosidic fragment and peptide was introduced into the structure 
of novel Haspin-tageting ARCs, leading to the generation of Set A (A) and Set B (B) of 
novel Haspin-targeting conjugates. 
 
 
Set A: Linkage via N-Terminal Region of Histone H3(1-7) Analogue 
Peptide (Compounds 1-13) 
ARC-1141 was used as the starting compound for the novel conjugates of Set 
A. Novel conjugates of Set A incorporated AMTH as ATP-site binding frag-
ment and had amidated C-terminus (schematic structures are given in Table 8). 
The amidation of C-terminus was required due to the synthetic rationale as well 
as to mask the negative charge of carboxylate of C-terminus, which was 
expected to improve the affinity of conjugates for Haspin as a basophilic PK. 
Other structural variations among the conjugates included acylation of N-
terminus of H3(1-7) analogue peptide as well as introduction of linkers with 
variable length and flexibility. Moreover, in some cases the hexa-(L / D)-argi-
nine fragment was incorporated to the N- or C-terminus of H3(1-7)-like peptide. 
The purpose of latter structural modification was to improve the cell plasma 
membrane-penetrative properties178 of compounds and thus to facilitate the 
internalization of conjugates into the live cells in the following studies. Further-
more, the addition of number of positive charges of oligoarginine fragment was 
proposed to lead to the gain in affinity towards Haspin.  
The overlay of co-crystals of ARC-1141 versus H3(1-7) revealed that Ala1 
of H3(1-7) located near the DAla moiety of ARC-1141 (Figure 25). Thus, in 
Compounds 1-7, Ala1 of H3(1-7) was replaced with DLys (Figure 26). The 3D-
structure reavealed that Ala1 of H3(1-7) pointed away from the ATP-binding 
site; therefore, it was expected that the change of chirality from L to D should 
compensate for this difference and ‘flip’ the side-chain of DLys towards the 
 
71 
ATP-side. Next, the linker as well as AMTH moiety was conjugated with the 
peptide via the side-chain of DLys. Differently from the previous, in Com-
pounds 8-13, Ala1 was substituted with D-diaminopropionic acid moiety 
(DDap) and via its N-terminus, the linker and nucleosidic moiety were con-
nected with the peptide (Figure 26).  
 
 
Figure 26. The structures of Compound 4 and Compound 8. D-diaminopropionic acid 




The affinities of novel conjugates (note: Set A as well as Set B) were deter-
mined in displacement assay with FA readout by using the fluorescent probe 
ARC-1081. As a reference compound, ARC-1141 was used. In order to find 
out whether the new conjugates are potentially selective towards Haspin, the 
affinities of conjugates for catalytic subunit of cAMP-dependent protein kinase 
(PKA C) serving as a basophilic reference PK were also established (Table 8). 
The displacement data revealed that all the conjugates of Set A showed 
lower affinity compared to the starting compound ARC-1141 (Table 8). Never-
theless, the selectivity of novel conjugates (except Compound 8) towards 
Haspin over PKA C was improved by one to three orders of magnitude com-
pared to ARC-1141, thus demonstrating the rationale behind replacement of 
oligoarginine fragment with H3(1-7). The acylation of N-terminus of H3(1-7) 
fragment of conjugates led to the approximately 2-fold drop in affinity for 
Haspin; for instance, Compound 1 with acylated N-terminus possessed Kd 
value of 15000 nM versus Compound 4 possessed Kd value of 8800 nM. The 
drop of affinity could be explained by disruption of H-bond between Ala1 of 
H3(1-7) and Glu613 of Haspin resulted in acylation of N-terminus. Also, the 
acylation may mask the positive charge of the free amino group of N-terminus 
of peptidic fragment, which could be preferred by Haspin (as well as PKA C). 
The best affinity compound of Set A without Arg6 peptide towards Haspin was 
represented by Compound 8 (Kd value of 5200 nM), as the following optimi-
zation (including the introduction of rigid cycles, direct linkage of AMTH 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































As expected, the incorporation of Arg6 motif led to the remarkable increase in 
affinity of conjugates (Kd value of 120 nM for Compound 6 versus Kd value of 
13000 nM for Compound 5). The selectivity profiling towards Haspin and 
PKA C revealed that the positioning of Arg6 motif at the N-terminus of H3(1-7) 
was preferred by PKA C, while the positioning of hexaarginine at the C-
terminus of H3(1-7) was preferred by Haspin (Compounds 2 and 3 versus 
Compound 6 and 7, respectively). Notably, the latter supported the previous 
observations that Haspin preferably phosphorylates the residues near the N-
terminus of substrates and the attachment of longer sequences to the N-terminus 
of phosphorylatable residue disrupts the recognition of substrates by Haspin.179   
 
Set B: Linkage via Phosphorylatable Region of Histone H3(1-7)-like 
Peptide (Compounds 14-23) 
ARC-902 was used as a starting compound of Set B. The overlay of co-crystals 
of ARC-902 versus H3(1-7) with Haspin indicated that the side chain of first 
DArg residue following the linker of conjugate positioned in proximity of the 
phosphorylatable Thr3 of H3(1-7) (Figure 25). Similarly to Set A, all the 
conjugates incorporated amidated C-terminus of H3(1-7) peptide, whereas two 
strategies were used to link the Adc moiety and histone peptide.  
In the first case (Compound 14), Thr3 of H3(1-7) was replaced with LAsp 
(Figure 27). The side-chain of LAsp was used to link Adc via the side-chain of 
DLys, which, at the same time, functioned as a chiral spacer. Also, on synthetic 
rationale, Thr6 of H3(1-7) was substituted by LAla and the N-terminus of H3(1-
7) was acylated. In the second case (Compounds 15-23), Thr3 of H3(1-7) was 
substituted by LLys, to which side-chain Adc was connected via a set of linkers 
(Figure 27). The other structural variations included the introduction of different 
linkers with variable length and flexibility between the peptide and Adc moiety, 
and, in one case, Adc moiety was replaced with AMTH (Compound 21). 
Analogously to Set A, in some cases the hexa-(L / D)-arginine fragment was 
incorporated to the N- or C-terminus of H3(1-7)-like peptide.  
 
Figure 27. The structures of Compound 14 and Compound 15. The chiral spacer 




Again, with the aim to establish the initial selectivity properties, the affinity of 
conjugates for basophilic PKA C was also determined. The Kd values of conju-
gates towards Haspin as well as for PKA C together with the selectivity indices 
are shown in Table 9. 
The compounds from the Set B possessed generally higher affinity as well as 
selectivity towards Haspin compared to Set A. Still, the affinity data for novel 
conjugates of Set B confirmed the previously observed trends of structure-
affinity relationship. In particular, the acylation of N-terminus of modified 
H3(1-7) peptide led to dramatic, i.e., 20-fold drop in affinity (Kd value of 5200 
for Compound 14 versus Kd value of 170 nM for Compound 15). On the 
contrary, the introduction of Arg6 fragment led to the significant increase of 
affinity and resulted in conjugates with subnanomolar Kd value (Kd value of 
0.42 nM and 0.88 nM for Compound 18 and 19, respectively), thus showing 
higher affinity than the reference compound 5-ITu (Kd value of 3.9 nM).  
Importantly, the chiral spacer (D-amino acid) in the structure of linker was of 
utmost importance for the suitable binding of conjugates to Haspin. The affinity 
of compounds where the chiral spacer was replaced with a linear chain of 
approximately same length dropped significantly (Kd value of over 15000 nM 
for Compound 20 versus Kd value of 170 nM for Compound 15). This con-
firmed the previous observation that a long flexible linker facilitates the binding 
of a bisubstrate inhibitor to its target106; still, the chiral spacer in the structure of 
linker fragment may be required to direct the peptidic part of the conjugate 
towards the substrate-binding site.126 Again, the location of Arg6 fragment con-
firmed the aforementioned notion that its positioning at C-terminus of H3(1-7) 
peptide is needed to achieve selectivity towards Haspin over PKA C (Com-
pound 18 and 19 with selectivity indices of 90 and 30, respectively, versus 
Compound 22 and 23 with selectivity indices of 0.1 and 1, respectively). 
The most efficient novel conjugates without Arg6 fragment possessed Kd 
value around 100-170 nM (Compounds 15-17). In addition to modest affinity, 
Compound 16 (Kd of 150 nM) showed 50-fold higher affinity for Haspin than 
PKA C. The latter effect was probably due to the free carboxylate instead of 
amide at the C-terminus of chiral spacer, as its counterpart Compound 15 with 
amide showed comparable affinity towards Haspin (Kd value of 170 nM), but 5-
fold lower selectivity index.  
However, introduction of fatty acid Myr moiety into the structure of con-
jugate improved the affinity towards PKA C 40-fold, while the Kd value for 
Haspin remained in the same range (Compound 17 versus Compound 16). 
This observation confirmed the trend previously established for ARCs from the 
initial set (Table 5), and could probably be attributed to the fact that Myr moiety 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































Finally, it was established that the separate fragments of conjugates (i.e., ATP 
site-targeting fragment with linker and chiral spacer or H3(1-7) peptide with 
Arg6 fragment) alone possessed low affinity towards Haspin (Table 9). Hence, it 
demonstrated the importance of conjugation of fragments targeting different 
sites of Haspin.   
 
Selectivity Profiling of Novel Conjugates in a Panel of PKs 
Based on the results established in displacement assay (Table 8 and Table 9), 
two novel conjugates were chosen for the following selectivity profile deter-
mination towards a panel of 43 kinases (commercial inhibition assay carried out 
by Carna Biosciences). One of the selected conjugates incorporated only H3(1-
7)-like sequence in its peptidic part (Compound 15; final total concentration in 
the assay of 5 μM), whereas the other comprised both H3(1-7) sequence as well 
as Arg6 fragment (Compound 18; final total concentration in the assay of  
1 μM). As a reference, the selectivity data of ARC-902 (final total concentra-
tion in the assay of 1 μM) obtained in the previous studies121 was included for 
comparison.  
The panel of PKs included important players in mitosis (e.g., Aurora PKs, 
families of Cdk and Nek) as well as several basophilic PKs (e.g., families of 
Akt, Pim, ROCK). An abbreviated table of the inhibition percentages of novel 
conjugates and reference compound ARC-902 are given in Table 10. The 
complete dataset is presented in the corresponding publication (Paper I: Kestav 
et al., 2015).127 
The results revealed that Compound 18 possessed wide selectivity profile 
and inhibited a variety of PKs to the extent over 80%, including most of the 
basophilic PKs (i.e., AGC and CAMK groups, Aurora B, Clk1). Moreover, 
Compound 18 inhibited important mitotic players in families of Cdk (except 
Cdk7 and Cdk9) and Nek (except Nek2 and Nek7). As expected, the acidophilic 
PKs (i.e., Cdc7, CK2, Plk family) were not inhibited. The negative inhibition 
percentage values may either be explained by the fact that the compound 
activated PKs – or, more likely, that the compound reduced the non-specific 
binding of PKs to the surfaces. Also, the selectivity profile of Compound 18 
was analogous to the reference compound ARC-902, wherein Aurora B, 
Cdk2/CycA, Nek6, Pim2 and PKCα were inhibited to even greater extent. 
Overall, based on data above, it can be concluded that the positively charged 
oligoarginine fragment made the conjugates attractive for basophilic PKs, 
despite the histone fragment in the structure of compound.  
On the other hand, Compound 15 showed significantly less wide selectivity 
profile even at 5-fold higher concentration (note: 5 μM concentration was 
chosen due to the lower affinity of Compound 15 for Haspin compared to 
Compound 18). Remarkably, only 3 PKs out of 43 were inhibited over 80% 
(i.e., Haspin, PKA C, ROCK2) and 3 PKs were inhibited to the extent of 60-




Table 10. An abbreviated table of inhibition profiles of Compounds 15 and 18 together 
with reference compound ARC-902 (reported previously121) 
PK PK Group Compound 15 Compound 18 ARC-902 
    5 μM 1 μM 1 μM 
Akt1 (PKBα) AGC 46 97 98** 
Akt3 (PKBγ) AGC 28 94 - 
AurA other -19 48 - 
AurB other -8 87 -3*** 
AurC other -93 23 - 
BRSK2 (SAD-A) CAMK 24 57 - 
Cdc2 (Cdk1)/CycB1 CMGC 7 99 - 
Cdc7/ASK other -18 -146 - 
Cdk2/CycA2 CMGC 15 98 12*** 
Cdk2/CycE1 CMGC -2 88 - 
Cdk3/CycE1 CMGC 0 74 - 
Cdk4/CycD3 CMGC -7 72 - 
Cdk6/CycD3 CMGC 3 67 - 
Cdk7/CycH/MAT1 CMGC -4 -73 - 
Cdk9/CycT1 CMGC -1 23 - 
CK2α1/β other -5 -19 -4** 
Clk1 CMGC 58 102 - 
Haspin other 102 99 - 
MSK1 AGC 55 101 98*** 
Nek1 other 8 84 - 
Nek2 other 4 -23 18**** 
Nek6 other 2 61 6**** 
Nek7 other -2 37 42*** 
Nek9 other 15 65 - 
Pim1 CAMK 73 102 - 
Pim2 CAMK 59 102 62** 
PKA C AGC 98 100 89*** 
PKCα AGC 51 100 69*** 
Plk1 other -9 -84 19** 
Plk2 other 7 -56 - 
ROCK2 AGC 96 102 100*** 
     
Colour code: 
Colour % inhibition Colour % inhibition Colour % inhibition 
  below 20   40-60   above 80 
  20-40   60-80   no data 
Final total concentrations of ATP in the assay: * 1 mM; ** 5 μM; *** 20 μM;  
**** 50 μM; no asterisk, close to Km(ATP) value for a given PK. 
 
 
The focussed selectivity profile of Compound 15 demonstrated the successful 
design of Haspin-targeting selective bisubstrate-analogue inhibitor, as the selec-
tivity of substrate of Haspin translated into selectivity of H3-containing conju-
gates.   
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3. Co-Crystal Structures of Haspin with  
Novel Selective Conjugates  
[Paper II: Lavogina et al., 2016] 
Prior to the given work, 9 crystal structures of catalytic domain of Haspin were 
deposited in RCSB Protein Data Bank (PDB) (Table 11). 
 
 












2WB8 452-798 - (apoenzyme) 2.15 2009 
52 
2VUW 465-798 5-ITu 1.8 2008 181 











1.8 2008 - 
3FMD 470-789 H89 2.0 2008 - 
3IQ7 465-798 5-ITu 2.0 2009 181 
4OUC 465-798 5-ITu, H3(1-7) 1.9 2014 54 
4QT7 465-798 SCH772984 1.4 2014 182 
5HTB 465-798 Compound 15 (ARC-3353) 1.7 2016 109 
5HTC 465-798 Compound 16 (ARC-3372) 1.5 2016 109 
 
 
Based on the previously established biochemical potency of novel Haspin-targeting 
conjugates, two conjugates were chosen for the co-crystallization with kinase 
domain of Haspin, i.e., Compound 15 (Kd value of 170 nM) and Compound 16 
(Kd value of 150 nM). Both of those incorporated Adc moiety and H3(1-7) 
analogue sequence, but no oligoarginine fragment (Figure 28). The difference 
between the conjugates lied in functional group located at the C-terminus of the 
chiral spacer: in case of Compound 15, it was amide, and in case of Compound 
16, it was carboxylate. Two high resolution crystal structures were obtained, where 
the binding mode were unambiguously defined for both conjugates. The data 
collection and refinement statistics are given in the corresponding publication 
(Paper II: Lavogina et al., 2016).109 The new co-crystal structures of conjugates 
with Haspin were compared with the previously published structures of Haspin 




Figure 28. Chemical structures of Haspin-targeting conjugates Compound 15 and 
Compound 16. 
 
Importantly, the structures confirmed the bisubstrate nature of inhibitors that 
occupied both ATP- and substrate-site of Haspin (Figure 29). At the same time, 
Compound 15 displayed one binding mode in its co-crystal with Haspin, but 
Compound 16 showed two binding conformations.   
 
Figure 29. Binding of novel conjugates to Haspin. A) Co-crystal structure of Com-
pound 15 with catalytic domain of Haspin. PK is shown as green cartoon; conjugate is 
depicted in ball-and-stick mode (C atoms grey, O atoms red, N atoms blue). B) Co-
crystal structure of Compound 16 with catalytic domain of Haspin. PK is shown as 
cyan cartoon; conjugate is depicted in ball-and-stick mode (C atoms magenta, O atoms 
red, N atoms blue). Adc moiety and H3(1-7)-like peptide are surrounded by black and 
red circles, respectively.       
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The ATP-site targeting fragment Adc formed characteristic H-bonds between 
the N1 and N6 atoms of purine and backbone of Glu606 and Gly608 in the 
hinge region (Figure 30). The hydroxyl groups of ribose moiety gave several H-
bonds with the side-chain of Asp611 and carbonyl of Gly653.50 Differently from 
the previous crystal structures of Haspin, the P-loop together with the α-ulH 
helix and its connecting loops (AAs 489-532) in N-lobe had shifted upward, 
causing more open conformation of kinase domain of Haspin. This observation 
could probably be attributed to positioning of the flexible aliphatic chain of Ahx 




Figure 30. Interactions of conjugates with Haspin. A) Co-crystal structure of Compound 
15 with the catalytic domain of Haspin. PK is shown as green cartoon; conjugate is 
depicted in ball-and-stick mode (C atoms grey, O atoms red, N atoms blue). B) Co-crystal 
structure of Compound 16 with catalytic domain of Haspin. PK is shown as cyan cartoon; 
conjugate is depicted in ball-and-stick mode (C atoms magenta, O atoms red, N atoms 
blue). The amino acid residues of Haspin interacting with inhibitor are shown as lines and 
are numbered; the hydrogen bonds are shown as black dotted lines; a black circle shows 
the location of the C-terminus of the chiral spacer of the conjugate. 
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Next, the C-terminus of linker of both conjugates gave the H-bonds with the tip 
of P-loop, i.e., Val494 and Phe495 in case of Compound 15 and 16, respec-
tively (Figure 30). This interaction is not unique for Haspin and an analogous 
polar contact had been previously seen in the co-crystal structures of ARCs with 
PKA C.107,177 Generally, the aromatic side-chain of Phe495 is folded under the 
P-loop and is required for catalysis as it coordinates the β-phosphate of ATP; in 
the structure of inactive PKs, this Phe residue is ‘pushed out’ from under the P-
loop as the structure of PK is not prepared for catalysis.16,17 In case of structure 
of Compound 15 with Haspin, Phe495 was positioned perpendiculary to the P-
loop, hence favouring the hydrophobic stacking between the amide bond 
following the linker of the conjugate, the side-chain of Phe495 and the side-
chain of Lys527 (Figure 31). In case of Compound 16, the side-chain of 
Phe495 was completely ‘pushed out’ from under the P-loop. Furthermore, 
Phe495 contributed to the formation of hydrophobic pocket, which also 
included side-chains of Val494 and Lys527 as well as Lys residues in the 




Figure 31. Overlay of the co-crystal structures of Compound 15 (green) and Com-
pound 16 (cyan) with PDB entry 4OUC (pink) and 3DLZ (yellow). PK is shown as 
cartoon; Phe495 from the P-loop is depicted as sticks. AMP is shown as ball-and-stick 
mode (C atoms yellow, O atoms red, N atoms blue, P atoms orange).  
 
 
Generally, the H3(1-7)-like peptide in the structure of conjugates showed the 
characteristic U-turn, whereas the ‘bending out’ occurred at Lys residue 
corresponding to Lys4 in the structure of H3 (Figure 32).54 On the other hand, 
the binding mode of rest of the peptide differed considerably from the pre-






Figure 32. Interactions of H3(-like) peptide with Haspin. A) Co-crystal structure of 
Compound 15 with kinase domain of Haspin (PDB 5HTB). PK is shown as green 
cartoon; peptidic fragment of conjugate is shown as sticks; ATP-site fragment together 
with the linker part are shown as lines. B) Co-crystal structure of Compound 16 with 
kinase domain of Haspin (PDB 5HTC). PK is shown as cyan cartoon; peptidic fragment 
of conjugate is shown as sticks; ATP-site fragment together with linker part are shown 
as lines. C) Co-crystal structure of H3(1-7) with kinase domain of Haspin (PDB 4OUC). 
PK is shown as magenta cartoon; peptide is shown as sticks. D) Overlay of backbone of 
H3(1-7) peptide (magenta) with peptidic fragment of Compound 15 (grey) and 
Compound 16 (cyan) in co-crystals with Haspin (PK is not shown for clarity).  
 
 
In PDB 4OUC, Ala1 of H3 was bound into the small pocket on the surface of 
Haspin, whereas its N-terminal primary amine gave the H-bond with Glu613 in 
Haspin.54 However, in the new structures, the corresponding Ala residue was 
not positioned into this pocket, but gave the H-bond with the side-chain of 
Gln718 (Figure 30). The repositioning of Ala residue could probably be 
attributed to the different positioning of its adjacent Arg (corresponding to Arg2 
in H3) in the co-crystals of conjugates, allowed by more ‘open’ conformation of 
kinase due to the flexible Ahx linker (see above). In the previously published 
structure (PDB 4OUC), Arg2 was buried into the hydrophilic pocket of N-lobe 
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and gave a polar contact with Asn588 positioned at the upper layer.54 Diffe-
rently, in co-crystals of Haspin with conjugates, the side-chain of the corres-
ponding Arg residue pointed downward, whereas this position was stabilized 
via charge-assisted H-bonds with Asn654 and Asp687. 
Next, the repositioning of Arg residue (corresponding to Arg2 in H3) in the 
co-crystals of conjugates affected the binding of rest of the residues in peptidic 
fragment. Due to the charge-assisted H-bonds with Asn654 and Asp687 in the 
structure with Compound 16, the C-terminal carboxyl group of chiral spacer 
was moved towards Arg residue of conjugate (Figure 32). In the structure with 
Compound 15, the latter movement did not occur; instead, the C-terminal 
amide formed an intramolecular H-bond with the carbonyl of Lys residue 
(corresponding to Lys4 in H3). As a result, Lys was able to give the charge-
assisted H-bond with Asp707 and Asp709, which was also seen in structure of 
4OUC. However, in case of Compound 16, the interaction of Lys with Asp709 
was missing, hence allowing two different conformation of Lys of conjugate 
when bound to Haspin. In one conformation, this Lys developed H-bond only 
with Asp707. In another conformation, the side-chain of Lys participated in the 
formation of the aforementioned hydrophobic pocket (including Val494, 
Phe495, and Lys527) and additionally gave H-bond with Ser524 (Figure 32). 
Furthermore, the C-terminal part of H3(1-7)-like peptide adopted different 
conformation in co-crystals of conjugates with Haspin compared to the native 
H3(1-7). In case of the native H3 peptide, amide of Gln5 gave H-bond between 
Gly713 and Asp714 (activation loop of Haspin), whereas the rest of peptide was 
directed towards the N-lobe of Haspin (Figure 32). Differently, in complexes of 
Haspin with novel conjugates, the corresponding Gln residue together with the 
rest of C-terminal fragment was folded upwards and, at the same time, directed 
into solvent. However, in case of Compound 15 (note: Lys in peptidic part in 
one conformation, see above), the peptidic fragment of conjugate located closer 
to the N-lobe of Haspin, while the H-bond was formed between the Thr 
(corresponding to Thr6 in H3) and the side-chain of Asn588. In case of Com-
pound 16 (note: Lys in peptidic part in two conformations, see above), the C-
terminal fragment of peptidic part adopted different conformations, whereas the 
H-bond formed between the Thr (corresponding to Thr6 in H3) and Asn522 
(Figure 32). 
Overall, the co-crystal structures of novel conjugates with Haspin confirmed 
the bisubstrate nature of conjugates. Also, Haspin-bound conjugates maintained 
the main signature binding modes of both Adc moiety and H3 sequence. At the 
same time, it was demonstrated that small variation in the structure of com-
pounds (i.e., different C-termini of chiral spacer) may cause a considerable 
rearrangement of the spatial structure of the conjugate-PK complex.     
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4. Design and Biochemical Characterization of  
New Set of Haspin-Targeting Conjugates  
[Paper III: Kestav et al., 2017] 
Itc-Incorporating Novel Haspin-Targeting Conjugates 
As the affinity of the previously discussed most potent novel conjugates lacking 
Arg6 sequence (Compound 15 and 16) remained at the moderate range, the 
following development involved the improvement of affinity as well as selectivity 
of conjugates towards Haspin over other PKs. It was assumed that the replace-
ment of Adc moiety (Kd value of 15 μM for Haspin) with 5-ITu (Kd value of 4 nM 
for Haspin) could result in improved affinity. The comparison of the co-crystal 
structures of Haspin with Compound 15 (PDB 5HTB) and 16 (PDB 5HTC) 
versus Haspin with 5-ITu:H3(1-7) (PDB 4OUC) revealed that the incorporation 
of 5-ITu did not require the readjustment of linking unit between the nucleosidic 
fragment and peptide (Figure 33). However, the incorporation of 5-ITu into the 
structure of conjugates required chemical modification of the compound, i.e., 
oxidation of the 5´-hydroxyl of ribose to a carboxylic acid, resulting in 5-




Figure 33. Comparison of binding patterns in ternary complex of Haspin with 5-ITu 
and H3(1-7) (PDB 4OUC; A), and binary complex of Haspin with Compound 15 (PDB 
5HTB; B). PK is shown as cartoon; 5-ITu, H3(1-7) and Compound 15 are shown in 
ball-and-stick mode (C atoms grey, O atoms red, N atoms dark blue); H-bonds are 
shown as black dotted lines; residues of PK that form the interactions with the co-
crystallized compounds are shown as lines. The water molecule discussed in the text is 
depicted as a green sphere.  
 
 
Not surprisingly, the replacement of Adc with Itc (Compound 26) resulted in 
significant increase in affinity of the conjugate (i.e., possessed subnanomolar 
range of affinity) compared to its Adc counterparts (Compound 15 and 16) or 
reference compound 5-ITu (Table 12). Furthermore, the selectivity of Itc-
incorporating conjugate towards Haspin over PKA C was remarkably improved. 
Thus, Compound 26 served as an outstanding example of a novel Haspin-
targeting compound possessing picomolar affinity as well as improved selecti-






























































































































































































































































































































































































































































































































































































































































































































































































































































































Design of Fluorescent Probes (Compounds 27-30) 
The novel conjugates incorporating Adc or Itc moiety and modified H3(1-7) 
sequence in peptidic part were converted into fluorescent probes by linking 
TAMRA dye via the side chain of C-terminal Lys residue of the compounds (Table 
12). This modification also allowed the further investigation of kinetic 
characteristics of the novel probes. Furthermore, the fluorescent probe with Myr 
moiety was synthesized as in previous studies with PKA C, Myr moiety had shown 
to improve cell plasma membrane-penetrating properties of conjugates.183 The 
equlibrium dissociation constants of probes were established by using binding assay 
with FA readout (Table 12). Again, PKA C was used as basophilic reference PK. 
The labelling of Itc-incorporating Compound 26 led to the formation of 
Compound 27. Importantly, the obtained probe maintained subnanomolar 
affinity (KD value of 0.5 nM), but, on the other hand, the selectivity index 
towards Haspin over PKA C decreased significantly from 4900-fold to 34-fold 
(Table 12). Next, the labelling of Compound 16 yielded Compound 28, which 
possessed increased affinity towards both Haspin and PKA C (selectivity index 
of 14- and 148-fold, respectively), but, again, the selectivity for Haspin de-
creased remarkably. The incorporation of Myr moiety (Compound 29) im-
proved the affinity only for PKA C. 
The decrease of selectivity of novel probes towards Haspin over PKA C can 
be attributed to the fact that the hydrophobic TAMRA dye as well as Myr 
moiety could interact with hydrophobic (P+1)-binding pocket in the substrate 
site of PKA C184, hence improving the affinity of probes towards PKA C. 
Compound 19 comprising Arg6 fragment was used as a backbone to derive 
the fluorescent probe Compound 30, which showed slighly decreased selec-
tivity towards Haspin versus PKA C (selectivity index of 20 in case of Com-
pound 30 versus selectivity index of 30 in case of Compound 19; Table 12). In 
this way, the maintenance of selectivity towards Haspin confirmed the impor-
tance of positioning of oligoarginine fragment (see above).  
Overall, it was demonstrated that the incorporation of fluorescent dye into 
the structure of conjugates may lead to considerable changes in the biochemical 
characteristics of compounds. The effect may be insignificant in general bio-
chemical assays, where purified targets are often used, but, in turn, should 
definitely be taken into account in more complex biological systems (e.g., living 
cells, cell lysates, bodily fluids). 
 
Determination of Kinetic Properties of Fluorescent Probes by Using 
Assays with FA Readout 
Besides the high affinity as well as selectivity of a small molecular compound 
(inhibitor) to its biological target, the dissociation kinetics of the drug-target 
complex (or the residence time of inhibitor) has recently gained much attention. 
The long residence time leads to the durable (pharmacological) effect and 
reduced toxicity of the compound.185,186 Furthermore, the kinetic properties of 
the compound can reflect the binding mode of the ligand to its biological 
target.80 The common approach for describing the ligand-target interactions to 
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date is a double-induced-fit model, where the association (kon) of the ligand with 
its target is accompanied with the conformational adaption of 3D-structures of 
both the ligand and target protein. Thereby, the association process may be 
relatively slow and include several steps.186–188 With the aim to determine the 
correlation between the structural features, the kinetic profile as well as the 
binding mode of conjugates, the association and dissociation of new compounds 
and a previously reported reference compound (incorporating only Arg6 frag-
ment in peptidic part) were established in studies with Haspin.  
First, the association constants of fluorescent probes Compounds 27-30 and 
the reference compound ARC-583 were determined from the increase of aniso-
tropy during the association of probes with Haspin. Slow association kinetics for 
Itc-incorporating Compound 27 (kon=6.11 × 105 M-1 s-1; Table 13; Figure 34, A) 
was found. Its Adc-containing counterpart, Compound 28 possessed 4.3-fold 
faster association than Compound 27. The association constant of Compound 29 
comprising Myr moiety was in the same range as that of Compound 28. 
Importantly, the association rate constants of all compounds (Compound 27-
29) incorporating the N-terminal H3-like sequence were by over 10-fold smaller 
than that of the reference compound ARC-583, which contained only oligoarginine 
sequence in its peptidic part (Table 13). On the other hand, the incorporation of 
oligoarginine fragment to the C-terminus of H3 sequence (Compound 30) led to 
4.4-fold increase of the association rate. Based on the established data, it was con-
cluded that the sequence of H3 caused slow association kinetics, but, on the other 
hand, the incorporation of oligoarginine fragment resulted in increase of the as-
sociation rate constant. The slow association kinetics was also observed in thermal 
shift assay (see below) in case of conjugate Compound 26 comprising Itc moiety.  
Thereafter, the dissociation rate constants of fluorescent probes were deter-
mined from the decrease of anisotropy values during the dissociation of a probe 
from the complex with Haspin in the presence of large excess of displacing 
compound (ATP-site inhibitor 5-ITu or bisubstrate inhibitor ARC-902). The 
compounds that comprised Adc moiety as the ATP-site targeting fragment did not 
show uncommonly slow dissociation (Table 13). On the other hand, Compound 
27 possessed extremely slow dissociation kinetics, and hence required a different 
experimental setup for determination of the dissociation constant. In particular, 
the data points were taken within 5 h, whereas the signal of free probe was used 
as a minimum value of anisotropy for fitting the data (Figure 34, B). According to 
the measurements, Compound 27 showed remarkably long residence time of 4.5 
h (Table 13). The comparison of the residence times of compounds revealed that 
the Adc moiety-incorporating counterpart Compound 28 had 160-fold shorter 
residence time than Compound 27. Moreover, the incorporation of oligoarginine 
fragment to the C-terminus of H3(1-7) analogue sequence (Compound 30) 
resulted in increase of the residence time around 2-fold. On the other hand, the 
addition of Myr (Compound 29) led to 8-fold reduction of residence time 
compared to Adc-incorporating Compound 28 (Table 13). Finally, the reference 
probe ARC-583 (incorporating Adc moiety and oligoarginine fragment, but no 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 34. Association and dissociation kinetics measurements for the complex of 
Compound 27 and Haspin. A) Association of Compound 27 (1 nM) with Haspin (2 
nM). The data are fitted to the second-order association kinetics equation. As controls, 
free probe and pre-mixed PK-bound probe were used. The data of one representative 
experiment are shown (N=6). B) Displacement of Compound 27 (2 nM) from its 
complex with Haspin by 5-ITu (20 μM). The data are fitted to the first-order 
dissociation kinetics equation. The signal of free probe was used to define the minimum 
anisotropy value. The data of 2 representative experiments are shown (N=3).  
 
 
Based on the obtained data, the equilibrium dissociation constants (KD’) were 
calculated, whereas the results showed the good accordance of KD’ values with 
dissociation constants (KD) obtained from the binding assay with FA readout 
(Table 4, Table 12, Table 13).   
 
Determination of Kinetic Properties of Compounds Devoid of  
Long-Lifetime Photoluminescence by Using Photoluminescent Probe 
ARC-1063 
In order to show whether the very slow dissociation kinetics of 5-ITu containing 
conjugates was caused by the nucleosidic moiety, H3(1-7) imitating peptide or 
the cooperative effect of both fragments, the binding kinetics for non-labelled 
compounds Compound 26 and 5-ITu was additionally established. For this, the 
PK binding-responsive photoluminescent bisubstrate probe ARC-1063 was 
used, which possesses strong long-lifetime (in microsecond scale) photo-
luminescence at 647 nm after pulse-exitation at 337 nm (measured in 80–480 μs 
time-window) in complex with PK. Furthermore, ARC-1063 gives a negligible 
background signal as a free probe in solution (discussed in Methods under 
section 2.4. ARC-Lum(Fluo) Probes).133 Due to the slow decay of photo-
luminescence of complex of the PK and ARC-1063, the probe allows measure-
ment of samples containing other fluorescent compounds not endowed with 
long-lifetime photoluminescence property. In binding assay with Haspin, ARC-
1063 showed KD value of 15 nM and, at the same time, fast kinetic properties 
(both association and dissociation; residence time below 10 s); thus, this probe 
is a suitable tool for the determination of kinetic data of compounds devoid of 
long-lifetime photoluminescence (non-Lum).  
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The association constants of non-Lum compounds were assessed as follows. 
Haspin was pre-incubated with ARC-1063 and, subsequently, an excess of non-
Lum competitive compound was added to the solution (Figure 35). The addition 
of competing compound led to the decrease of photoluminescence signal of 
ARC-1063, whereby the slower the association of non-Lum compound, the 
slower was the decrease of photoluminescence.  
 
 
Figure 35. Schematic illustration of measurement of association kinetics by using 
photoluminescent probe ARC-1063. PK is depicted as orange shape; photoluminescent 




Indeed, the results confirmed the slowest on-rate of Compound 27 (kon*=1.97 × 
106 M-1 s-1), which was followed by Compound 26 and 5-ITu (Table 14, Figure 
37). The association of the reference compound ARC-902 was so quick that its 
on-rate could not be determined with sufficient reliability with present assay. 
Importantly, the kon* value of Compound 27 determined with the current 
method was in good accordance with the kon value established in the binding 
assay with FA readout (5.41 × 105 M-1 s-1 versus 6.11 × 105 M-1 s-1). 
To establish the dissociation constants of non-Lum compounds, Haspin was 
pre-incubated with a non-Lum compound; thereafter, ARC-1063 was added in 
large excess (100- to 500-fold excess compared to non-Lum compound) and 
establishment of luminescence signal was monitored (Figure 36). The addition 
of ARC-1063 caused increase of luminescence signal of ARC-1063 due to the 
dissociation of non-Lum compound from PK and the subsequent binding of 
large excess of ARC-1063 with Haspin. Hence, in case of non-Lum compound 
with slow dissociation kinetics, the increase in photoluminescence is likewise 
slow. The obtained data was fitted to the one-phase exponential association 
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Figure 36. Experimental layout for measurement of dissociation kinetics by using 
photoluminescent probe ARC-1063. PK is depicted as orange shape; photoluminescent 




As expected, Compound 26 possessed the slowest dissociation from Haspin 
and a remarkably long residence time of 7.2 h. This was followed by Com-
pound 27 and 5-ITu (Table 14, Figure 37). As in case of association assay, it 
was not possible to determine the dissociation rate constant for ARC-902 with 
sufficient reliability due to its very fast dissociation from Haspin. Again, the 
koff* value of Compound 27 was in good agreement with the koff value 
established in the assay with FA readout (koff* values of 6.68 × 10
-5 s-1 and  
6.13 × 10-5 s-1, respectively).  
Again, based on the kinetic data obtained from the photoluminescence assay, 
the equlibrium dissociation constants (KD*) were calculated as the ratio of 
corresponding rate constants (koff*/ kon*). The KD* values of Compound 27 and 
5-ITu were in reasonably good accordance with dissociation constants (KD) 
obtained from the binding/displacement assay with FA readout (Table 14). On 
the contrary, the KD* value for Compound 26 (KD* value of 0.019 nM; Table 
14) was significantly different from the apparent KD value established in assay 
with FA readout (Kd value of 0.14 nM; Table 12), where the true equilibrium 
was not reached.  
Slow dissociation
 slower increase of 
photoluminescence
Fast dissociation












Figure 37. Examples of association and dissociation curves obtained by using the 
photoluminescent probe ARC-1063. A) Determination of association rate constant of 
Compound 26. B) Determination of association rate constant of Compound 27. The 
solid pink line represens the fit of data to the one-phase exponential decay equation. C) 
Determination of dissociation rate constants of Compound 26 and Compound 27. The 
signal of mixture was normalized to the signal of free probe (0%) and the signal of 
complex of Haspin with ARC-1063 (100%). The data were fitted to the one-phase 
exponential association equation.  
 
 
Based on the obtained results, it can be concluded that the slow binding kinetics 
of Haspin with Compounds 26 and 27 is caused by both moieties of con-
jugates, Itc as well as H3(1-7)-like sequence. According to the overlay of the 
co-crystal structures of Haspin with 5-ITu and Compound 15, it is evident that 
in the region where the iodine of 5-ITu was bound, one water molecule was 
expelled from the kinase site (Figure 38). Thus, it may be assumed that the slow 
association kinetics of 5-ITu moiety could be partially attributed to the 
dehydration of the ATP-site of Haspin which is required for binding of 5-ITu.182 
Besides, it had previously been reported that the slow association kinetics of 5-
ITu is caused by the strong interactions between the electron cloud of iodine of 
5-ITu with the π-electrons of aromatic system of Phe605, whereas Phe605 
functions as the gatekeeper residue in Haspin (Figure 38).182 H3(1-7)-like 
peptide adopts unusual U-turn shape when bound to Haspin, the conformational 
adaption of peptide may be relatively time consuming. In turn, disruption of this 
unusual conformation during the dissociation from Haspin could lead to the 







Figure 38. Co-crystal structures of Haspin kinase domain with Compound 15 (PDB 
5HTB) and 5-ITu (PDB 4OUC) for the comparison of binding patterns. A) The binding 
of 5-ITu to ATP-site of Haspin. PK is shown as a magenta cartoon and the inhibitor is 
presented in ball-and-stick mode (C atoms cyan, O atoms red, N atoms dark blue, I 
atoms violet). B) The binding of Adc moiety of Compound 15 to ATP-site of Haspin. 
PK is shown as a green cartoon and the inhibitor is presented in ball-and-stick mode (C 
atoms grey, O atoms red, N atoms dark blue). The residues of PK that form the 
interactions with the co-crystallized inhibitor are shown as lines; hydrogen bonds are 
shown as black dotted lines. The gatekeeper residue Phe605 is labelled and highlighted 
as sticks. The water molecule discussed in the text is depicted as a magenta sphere. 
 
 
On the other hand, the very fast binding of ARC-583 and Haspin may be attri-
buted to the non-oriented charge-charge interactions of positively charged 
guanidinium groups of oligoarginine fragment with the negatively charged 
substrate-binding site of Haspin. From the co-crystal structure of ARC-902 
(representing the non-fluorescent analogue of ARC-583) with Haspin, it was 
evident that the electron density of peptidic part of ARC-902 was defined only 
for three arginine residues out of six, which indicated that the Arg6 fragment 
was rather flexible and most likely possessed several conformations when 
bound to Haspin (Figure 24).  
Finally, the temporal target selectivity of Compound 27 with reference 
basophilic kinase PKA C was established (Table 15). The temporal target selec-
tivity shows the difference how long is the compound bound to its desired target 
compared to the off-target(s): the longer the residence time of compound with 
its target and lower with other proteins, the lower is the off-target-derived 
toxicity.189 The results revealed that the temporal target selectivity (i.e., the ratio 




Table 15. Kinetic parameters of association and dissociation of Compound 27 with/from 
Haspin and PKA C established in the assay with fluorescence anisotropy readout 
Parameter Haspin PKA C 
kon, M-1 s-1 6.11 × 105 [0.58 × 105] 1.89 × 107 [0.51 × 107] 
koff, s-1 6.13 × 10-5 [0.66 × 10-5] 9.87 × 10-2 [1.84 × 10-2] 
τ, s 16 300 10.1 
Standard deviation values are given in square brackets (N ≥ 3). τ, residence time 
calculated as the reciprocal of koff.  
 
 
5. PK Selectivity of Itc-Incorporating Conjugate  
[Paper III: Kestav et al., 2017] 
Selectivity Profiling of Itc-Incorporating Novel Conjugate with  
Off-Targets of 5-ITu by Using Thermal Shift Assay 
The previously reported PK off-targets of 5-ITu are the CMGC kinase family 
Clks (Cdc2-like kinases) and PKs of the DYRK (dual-specificity tyrosine (Y)-
phosphorylation regulated kinases) family.54,90 Moreover, adenosine kinase 
(ADK) that belongs to the phosphofructokinase B family of sugar kinases is 
also acknowledged target of 5-ITu.92 ADK catalyses the γ-phosphoryl transfer 
from ATP to adenosine, resulting in the formation of ADP and AMP.190,191 
Hence, 5-ITu functions as both inhibitor of ADK (IC50 value of 26 nM) as well 
as substrate by competing with adenosine.92,192 In order to determine whether 
the addition of H3(1-7)-like peptide to 5-ITu increased the selectivity of con-
jugate over 5-ITu, the thermal shift assay was performed with Clk1, Clk2 and 
ADK. ARC-902 was used as the reference compound.  
Initially, in case of thermal shift measurement with Haspin, 15 min was 
chosen for pre-incubation time at room temperature after the components of 
assay were mixed on ice. The obtained melting curves of Compound 26 and 5-
ITu showed unusual shape with two peaks (Figure 39, A), whereas the first 
maximum of the curve was located close to the melting temperature of the 
native kinase and the second maximum was near the melting temperature of 
ligand-bound PK. Thus, it was assumed that the pre-incubation time of 15 min 
was not sufficient for binding of Compound 26 or 5-ITu to Haspin, since some 
amount of PK still remained native (first peak), but, at the same time, the other 
fraction was already ligand-bound (second peak). Therefore, the pre-incubation 
time of samples was extended up to 30 min and, as expected, the melting curves 
with normal-shape were obtained for both compounds (Figure 39, B). Again, 
this observation pointed indirectly to the slow association kinetics of Itc-






Figure 39. Examples of melting curves of Haspin in complex with the non-fluorescent 
conjugates and 5-ITu. A) Pre-incubation time 15 min at 30 °C. B) Pre-incubation time 
30 min at 30 °C. For determination of thermal shift values, three values after maxima 
were taken into account and Boltzmann equation was used for fitting of curves. Final 
total concentrations: Haspin 2 μM, compounds 12.5 μM. The volumes of deionized 
water and DMSO added as references corresponded to the maximal added volumes of 
inhibitor stock solutions in DMSO. RFU, relative fluorescence unit. 
 
 
The thermal shift assay results revealed that the established ΔTm values were in 
good agreement with the previously reported values (Table 16).90 Consistently 
with the data established in displacement assay (Table 9), the ΔTm value of 
Compound 26 in complex with Haspin was remarkably higher than that of its 
Adc-incorporating counterpart Compound 16 or 5-ITu (16.4 oC, 6.6 oC, and 
10.8 oC, respectively). On the contrary, ΔTm values of Compound 26 in 
complex with off-targets of 5-ITu showed significant decrease compared to the 
ΔTm values of 5-ITu with the corresponding PKs. Furthermore, even more 
significant decrease in ΔTm value of Compound 26 versus 5-ITu in complex 
with ADK was observed (from 15.4 to 5.0 oC). Based on the established data, it 
may be concluded that the incorporation of H3(1-7)-like peptide to the structure 
of conjugate not only improved its affinity towards Haspin, but also led to the 













































































































































































































































































































































































































Selectivity Profiling of Itc-Conjugate Towards In-House Panel of PKs 
With the aim to establish a wider selectivity profile of the Itc-comprising con-
jugate Compound 26, equilibrium binding/displacement assay was performed 
with an in-house panel of PKs. Additionally to Haspin and PKA C, the panel 
contained nine PKs, including basophilic kinases ROCK2 (Rho-associated pro-
tein kinase 2), MSK1 (mitogen- and stress-activated protein kinase-1), Akt3/ 
PKB (Rac-gamma serine/threonine-protein kinase; protein kinase B), Aurora A 
and B, acidophilic kinase CK2 and proline-directed kinases of the Pim family 
(proto-oncogene serine/threonine-protein kinase) Pim1, Pim2, and Pim3 (Table 
17). 5-ITu was used as the reference compound in all experiments.  
The results revealed that Compound 26 possessed sub-micromolar affinity 
only for two PKs out of nine, i.e., Pim3 (Kd of 370 nM) and ROCK2 (Kd of  
700 nM). However, these Kd values were significantly higher compared to the 
subpicomolar Kd value of Compound 26 towards Haspin (Kd* of 0.019 nM). 
Thus, the selectivity index of Compound 26 in favour to Haspin remained 
remarkably high (19000-fold over Pim3, and more than 1 600 000-fold over 
CK2). Also, 5-ITu showed high selectivity for Haspin; relative to Haspin, its 
lowest selectivity indices within this panel were for Aurora A and Pim1 (670- and 
750-fold, respectively). 
 
Table 17. Values of equlibrium dissociation constant and selectivity index of Com-
pound 26 and  5-ITu established in assays with different PKs 







Haspin 0.14 (0.05) 
[a] 
0.019 [b]  3.9 (0.4)  
PKA 94 (12) 4900 over 15 000 over 3800 
ROCK2 700 (80) 1600 10 300 (1000) 2600 
MSK1 4000 (1000) 9070 6700 (500) 1700 
Akt3 2700 (600) 6110 74 000 (3000) 19 000 
Pim1 3900 (200) 8880 2900 (200) 750 
Pim2 over 30 000 over 68 000 27 000 (5000) 6900 
Pim3 370 (120) 852 7300 (400) 1900 
Aurora A 15 600 (2000) 35500 2600 (100) 670 
Aurora B 2800 (600) 6340 6100 (2900) 1600 
CK2 over 30 000 over 68 000 25 000 (3000) 6500 
* Standard error values are given in brackets (N ≥ 3). ** The selectivity index was 
calculated as the ratio of the Kd values of an inhibitor in experiments with the 
corresponding PK and Haspin (in case of Compound 26, the Kd* value obtained from 
kinetic data was used). [a] Apparent Kd value (the true equilibrium had not been achieved 
after 30 min of incubation). [b] Equilibrium dissociation constant Kd* value calculated 
from the results of kinetic measurements. 
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To sum up, it can be concluded that the kinetic behaviour of conjugates is 
affected by the type of interactions between the ligand (conjugate) and PK. 
Hence, the slow association kinetics as well as the long residence time of con-
jugates comprising Itc moiety and H3(1-7)-like peptide result from the precise 
positioning of the ‘hotspots’ of specific interactions. On the other hand, the fast 
kinetic properties of oligoarginine-comprising conjugates can be attributed to 
the guanidinium groups of multiple arginine residues of the peptide moiety give 
relatively random and less localized interactions with the negatively charged 
substrate-site of Haspin. Besides the long residence time, the Itc-incorporating 
conjugate exhibited improved selectivity towards the selection of PKs (in-
cluding off-tagets of 5-ITu) compared to that of 5-ITu. Finally, the novel 
conjugates incorporating Itc moiety and H3(1-7)-like peptide serve as excellent 
examples of Haspin-selective compounds with long residence time.   
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CONCLUSIONS AND PERSPECTIVES 
Within this study, a new target represented by the mitotic basophilic protein 
kinase Haspin was taken under investigation. The chemical space of tested com-
pounds targeting Haspin has been relatively small. On the other hand, this 
protein kinase has been declared to be a promising target for development of 
drugs that could be suitable for regulation of uncontrollable division of cells 
(e.g., in case of cancer). Hence, taking advantage of the prior structural know-
ledge gained with X-ray analysis of complexes of inhibitors and Haspin as well 
as our initial results of structure-affinity studies with ARC-inhibitors, enabled 
the construction of novel bisubstrate inhibitors for Haspin. New conjugates 
incorporated an adenosine analogue Adc or a 5-iodotubercidin analogue Itc as 
the nucleosidic fragment and histone H3(1-7)-like peptide analogue sequence as 
the peptide moiety. The affinity of constructed inhbitors towards Haspin kinase 
as well as their selectivity towards several protein kinases was established in 
biochemical studies. The study also established the structural elements of the 
conjugates that affect the binding kinetics of the compounds.  
The main outcomes of the present thesis were as follows:  
 Biochemical screening of the initial set of ARC-scaffolds with variable 
structural features (including fluorescent probes as well as non-labelled 
conjugates) revealed the structure-affinity relationship for the structure-
guided design of novel Haspin-targeting conjugates. 
 Two most effective lead compounds (ARC-1141 and ARC-902) of the ini-
tial set were chosen for the co-crystallization with kinase domain of Haspin. 
The obtained crystal structures of binary complexes were compared with the 
available co-crystal structure of substrate peptide of Haspin (histone H3), 
providing clues for the further improvement of Haspin-targeting conjugates. 
 The novel Haspin-targeting conjugates comprised Adc, AMTH or Itc as the 
ATP-pocket fragment, and histone H3-like sequence as the peptidic part. 
These compounds showed improved selectivity towards Haspin over a 
basophilic reference kinase PKA C, and the importance of chiral spacer in 
the structure of linker fragment to obtain high affinity for Haspin (required 
for the correct positioning of the conjugates to Haspin as the chiral spacer 
directs the peptidic fragment of conjugate towards the substrate-site) was 
demonstrated.  
 Next, inhibitory potency of Adc-comprising Compounds 15 (incorporating 
only histone H3 sequence in peptidic part) and 18 (incorporating histone H3 
sequence plus oligoarginine fragment in peptidic part) was determined 
towards 43 PKs (included important players in mitosis). Compound 18 inhi-
bited a variety of basophilic protein kinases, whereas Compound 15 showed 
a narrow selectivity profile and hence demonstrated that the selectivity of 
substrate of Haspin translated into selectivity of H3-containing conjugates. 
 Two most potent lead compounds of novel conjugates comprising Adc and 
histone H3-like peptide (Compounds 15 and 16, possessing Kd values of 
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170 and 150 nM, respectively) were co-crystallized with Haspin. The ob-
tained 3D-structures of complexes featured high resolution and revealed that 
a small change in the structure of conjugates resulted in considerable diffe-
rence in binding modes of interacting partners; at the same time, the signa-
ture of point interactions of histone H3 peptide was maintained for the 
histone peptide if it was incorporated into structure of the conjugates. Also, 
the bisubstrate nature of compounds was confirmed.  
 The biochemical characterization of Itc- and histone H3(1-7)-like peptide-
incorporating conjugates revealed subnanomolar affinity of Compounds 26 
and 27 (KD* value of 0.019 nM and KD´ value of 0.100 nM, respectively). 
Moreover, Compounds 26 and 27 (TAMRA-labelled analogue of Com-
pound 26) possessed remarkably long residence times of 7.2 and 4.5 h, 
respectively.  
 Compound 26 showed improved selectivity towards a selection of PKs (in-
cluding off-targets of 5-iodotubercidin) compared to that of 5-iodotuber-
cidin, a nucleoside analogue that is actively used in biological research as a 
potent inhibitor of Haspin. 
 
Perspectives 
In future studies, the further development of Haspin-targeting inhibitors should 
first concentrate on improvement of the cell plasma membrane-penetrative 
properties as well as the proteolytic stability of conjugates. Briefly, in our initial 
studies, the effect of the developed inhibitors on the Haspin regulated histone 
H3 phosphorylation balance (established by monitoring decrease in the 
phosphorylation of Thr3 of histone H3) was low.127,128 The incorporation of 
either oligoarginine fragment or Myr moiety seemed to be insufficient for the 
successful internalization of Haspin-targeting conjugates into live cells. More-
over, the lack of significant effect of novel conjugates might be caused by 
degradation of conjugates by proteases in complex biological systems, as the 
histone H3 sequence in peptidic fragment of conjugates was built up of L-amino 
acids. One strategy to increase the proteolytic stability of compounds is the 
replacement of the ‘classical’ amino acid residues in peptidic fragment with 
peptidomimetics.97–99,193 Also, the cyclization of histone H3-like peptide in the 
structure of novel conjugates may improve the succesful internalization of con-
jugates into the live cells as well as improve the stability for proteolytic 
degradation in cellular milieu.194,195 Other strategies involve the linkage of 
transport peptide to the structure of conjugates (e.g., folate, RPARPAR, or 
nonaarginine) via disulphide bridge to enhance the cellular uptake of Haspin-
selective conjugates. The effect of transport peptides in the structure of ARC 
inhibitors had been demonstrated in our group when targeting acidophilic 
protein kinase CK2.135 Our group is currently working on the development of 
synthetic strategies for generation of conjugates of the latter classes. 
The perspective of the distant future could be to link the Haspin-targeting 
selective conjugates with the nano-based drug delivery carriers or nanocarriers. 
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An important benefit of nanocarriers is a site-specific delivery of compound to 
the tumor and hence the reduction of side effects and enhancement of efficiency 
of the drug.196,197 
Another application of novel Haspin-targeting conjugates requires immobili-
zation of the conjugates onto the surface. Thereafter, the surface-immobilized 
selective conjugates enable ‘fishing out’ of the kinase of interest from the 
various biological samples (e.g., cell lysates, bodily fluids), and the following 
detection allows the quantification of amount of the kinase in the sample. Such 
studies would enable assessment of the value of Haspin as a biomarker in 
various diseases. The initial experiments have confirmed applicability of our 
novel Haspin-targeting conjugates for generation of affinity surfaces, and we 






SUMMARY IN ESTONIAN 
Kristallstruktuuridest juhinduv bisubstraatsete inhibiitorite 
arendamine mitootilisele proteiinkinaasile Haspin 
Bioteadustes (sh farmaatsiatööstus) pannakse suurt rõhku sellele, et töötada 
välja ühendeid, mis oleksid võimelised reguleerima rakkude kontrollimatu jagu-
nemiseni viivaid signaaliradasid, st takistama (vähk)kasvajate arengut. Paral-
leelselt ravimiarendusega on ülioluline arendada lihtsa teostusega diagnostilisi 
meetodeid, mis võimaldaksid kindlaks teha haigusi juba varajases arenguetapis. 
Rakujagunemine (sh mitoos) on ülitäpselt reguleeritud teatud ensüümide pere-
konna – proteiinkinaaside – koostöö poolt. Proteiinkinaasid katalüüsivad fosfo-
rüülimist, mis toimib kui rakusisene märgis, käivitades või peatades signaali-
radade toimimist ning seeläbi reguleerides raku eluks vajalikke protsesse. Pro-
teiinkinaase kasutatakse ka biomarkeritena, kuna nende anomaalselt muutunud 
aktiivsust seostatakse erinevate haiguste tekke ja/või arenguga.  
Käesoleva töö käigus võeti sihtmärgiks üsna väheuuritud, kuid mitoosi regu-
latsioonis ülioluline basofiilne proteiinkinaas Haspin. Haspinit on nimetatud ka 
„paljutõotavaks sihtmärgiks inhibiitorite kui potentsiaalsete vähivastaste ravi-
mite arendamisel“.3 Haspinile suunatud ühendite konstruktsioonil kasutati Tartu 
Ülikooli meditsiinilise keemia uurimisrühmas arendatud bisubstraatsete inhibii-
torite adenosiini ja oligoarginiini konjugaatide (ARC-de) printsiipi: ATP-
sidumistaskusse seostuv nukleosiidne osa ning substraadi-taskusse seostuv 
peptiidne fragment (nt proteiinkinaasi substraadi analoog) ühendatakse paind-
liku linkeriga. Uute ühendite disain põhines informatsioonil, mis oli saadud  
nii Haspini koos-kristallstruktuuridest kui ka varasemalt sünteesitud laia selek-
tiivsusprofiiliga ARC-de struktuur-afiinsus sõltuvustel Haspini suhtes (tehti 
kindlaks ARC-de esialgse valimi biokeemilisel iseloomustamisel Haspiniga). 
Antud töö raames arendatud Haspinile suunatud konjugaadid koosnesid adeno-
siini analoogist (Adc) või Haspin-selektiivse inhibiitori 5-iodotubercidini 
fragmendist (Itc), mis ühendati linkeriga Haspini substraadi histoon H3 järjes-
tust jäljendava peptiidse osaga. Seejärel teostati Haspinile suunatud konjugaa-
tide afiinsuse, selektiivsuse ja kineetiliste omaduste uuringud.  
Antud uurimistöö peamised tulemused on järgmised: 
 Töö esimeses etapis teostati valim erineva struktuuriga olemasolevate ARC-de 
seast, sisaldades nii fluorestsentsonde kui ka märgistamata konjugaate. ARC-
konjugaatide biokeemilisel analüüsil Haspiniga tehti kindlaks struktuur-
afiinsus sõltuvused, mida kasutati Haspinile suunatud konjugaatide disainil. 
 Kaks kõige efektiivsemat ühendit (ARC-1141 ja ARC-902) algsest ARC-de 
valmist koos-kristalliti Haspiniga. Saadud binaarseid komplekse võrreldi 
eelnevalt publitseeritud Haspini substraadi histoon H3(1-7) peptiidi kristall-
struktuuriga ning saadud infot kasutati lisainformatsioonina järgneval Haspin-
selektiivsete ühendite konstrueerimisel. 
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 Uued Haspinile suunatud konjugaadid sisaldasid Adc, AMTH või Itc frag-
menti ning histoon H3(1-7) järjestust imiteerivat peptiidset osa. Uutel konju-
gaatidel oli parem selektiivsus Haspinile kui algühenditel (st ARC-1141 ja 
ARC-902, mis sisaldasid peptiidse osana oligoarginiini fragmenti), võrredes 
basofiilse referentskinaasiga PKA C. Lisaks näidati kiraalse elemendi olu-
lisus linkeri struktuuris. 
 Kahe Haspinile suunatud konjugaadi selektiivsusprofiil tehti kindlaks uurin-
gutes 43 proteiinkinaasist koosneva valimiga, mis hõlmas endas olulisi 
mitoosi-regulaatoreid. Konjugaat, mis sisaldas nii histoon H3 järjestust kui 
ka oligoarginiini fragmenti peptiidses osas, inhibeeris enamikke basofiilseid 
proteiinkinaase. Samas konjugaat, mis sisaldas ainult histoon H3 järjestust 
peptiidses osas, omas väga kitsast selektiivsusprofiili. Seega tõestati, et 
substraadi selektiivsed omadused säilisid konjugaadi struktuuris.   
 Kaks kõige efektiivsemat Haspin-selektiivset konjugaati, mis sisaldasid Adc 
ja histoon H3(1-7) sarnast peptiidi (Kd väärtus 150-170 nM), koos-kristalliti 
Haspiniga. Saadud kõrge resolutsiooniga kristallstruktuurid näitasid, et väi-
kesed muutused konjugaadi struktuuris põhjustavad arvestatavaid erinevusi 
ühendite seostumismustris. Sealjuures olid säilinud histoon H3-le iseloomu-
likud interaktsioonid ning tõestati uute konjugaatide bisubstraatne olemus. 
 Uued Itc and histoon H3(1-7) sarnast fragmenti sisaldavad konjugaadid oma-
sid subnanomolaarset afiinsust Haspinile ning olid märkimisväärselt aeglase 
dissotsatsioonikineetikaga. Lisaks oli paranenud ühendite selektiivsus, võr-
reldes 5-iodotubercidini kui konjugaadi ühe algfragmendiga. 
Haspinile suunatud konjugaatide edasise arenduse käigus peaks keskenduma 
ühendite rakumebraani läbimisvõime ja stabiilsuse parandamisele rakukeskon-
nas. Oma uurimistöö käigus oleme näidanud, et uute konjugaatide mõju Haspini 
signaaliradadele (jälgiti histoon H3 Thr3 fosforüülimise vähenemist elusrakku-
des) on ebapiisav.127,128 See võib olla põhjustatud konjugaatide kehvast raku-
membraani läbimisvõimest, kusjuures nii oligoarginiini fragmendi kui ka 
müristüülijäägi lisamine ei andnud märgatavat efektiivsuse kasvu.  Lisaks koos-
neb konjugaatide peptiidne osa L-aminohapetest, mida on võimelised proteaasid 
rakukeskkonnas lagundama. Võimalikuks strateegiaks on asendada „klassika-
lised“ aminohapped peptidomimeetikutega97–99,193 või tsükliseerida histoon H3 
imiteeriv peptiidne fragment.194,195 Teiseks võimaluseks on Haspin-selektiivsete 
konjugaatide struktuuri lisada transportpeptiidi järjestus (nt folaat, RPARPAR, 
nonaarginiini fragment), kasutades disulfiid-silda. Transportpeptiidide mõju 
ARC inhibiitorite struktuuris on meie uurimisrühmas eelnevalt uuritud seoses 
atsidofiilsele proteiinkinaasile CK2 suunatud konjugaatidega.135 
Käesoleva töö käigus arendatud Haspin-selektiivsete ühendite pikaajalise-
maks perspektiiviks on nende ühendamine nanokandjatega, mis võimaldaksid 
sihtmärkspetsiifilist transporti kasvajakoesse, suurendades seeläbi ühendite 
efektiivsust ning vähendades kõrvalmõjusid.196,197 Teiseks võimalikuks raken-
duseks on nende immobiliseerimine pinnale. Immobiliseeritud Haspin-selektiiv-
sete konjugaatidega on erinevatest bioloogilistest proovidest (nt rakulüsaadid, 
bioloogilised vedelikud) võimalik pinnale püüda kinaasi ning määrata Haspini 
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kui biomarkeri hulka proovis. Teostatud pilootkatsed on näidanud Haspinile 
suunatud konjugaatide rakendatavust afiinsuspindadena ning antud teemat on 
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